

## Connecting via Winsock to STM

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 MAR 31 Web Page for STN Seminar Schedule - N. America  
NEWS 2 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom  
IPC display formats  
NEWS 3 MAR 31 CAS REGISTRY enhanced with additional experimental  
spectra  
NEWS 4 MAR 31 CA/Caplus and CASREACT patent number format for U.S.  
applications updated  
NEWS 5 MAR 31 LPCI now available as a replacement to LDPCI  
NEWS 6 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements  
NEWS 7 APR 04 STN AnaVist, Version 1, to be discontinued  
NEWS 8 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new  
predefined hit display formats  
NEWS 9 APR 28 EMBASE Controlled Term thesaurus enhanced  
NEWS 10 APR 28 IMSRESEARCH reloaded with enhancements  
NEWS 11 MAY 30 INFAPAMDB now available on STN for patent family  
searching  
NEWS 12 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology  
sequence search option  
NEWS 13 JUN 06 EPFULL enhanced with 260,000 English abstracts  
NEWS 14 JUN 06 KOREAPAT updated with 41,000 documents  
NEWS 15 JUN 13 USPATFULL and USPAT2 updated with 11-character  
patent numbers for U.S. applications  
NEWS 16 JUN 19 CAS REGISTRY includes selected substances from  
web-based collections  
NEWS 17 JUN 25 CA/Caplus and USPAT databases updated with IPC  
reclassification data  
NEWS 18 JUN 30 AEROSPACE enhanced with more than 1 million U.S.  
patent records  
NEWS 19 JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional  
options to display authors and affiliated  
organizations  
NEWS 20 JUN 30 STN on the Web enhanced with new STN AnaVist  
Assistant and BLAST plug-in  
NEWS 21 JUN 30 STN AnaVist enhanced with database content from EPFULL  
NEWS 22 JUL 28 CA/Caplus patent coverage enhanced  
NEWS 23 JUL 28 EPFULL enhanced with additional legal status  
information from the epoline Register  
NEWS 24 JUL 28 IFICDB, IFIPAT, and IFIUDB reloaded with enhancements  
NEWS 25 JUL 28 STN Viewer performance improved  
NEWS 26 AUG 01 INFADOCDB and INFAPAMDB coverage enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \*

FILE 'HOME' ENTERED AT 10:20:56 ON 01 AUG 2008

=> file reg  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
FULL ESTIMATED COST ENTRY SESSION  
0.21 0.21

FILE 'REGISTRY' ENTERED AT 10:21:10 ON 01 AUG 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 JUL 2008 HIGHEST RN 1037244-07-7  
DICTIONARY FILE UPDATES: 30 JUL 2008 HIGHEST RN 1037244-07-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>  
Uploading C:\Program Files\Stnexp\Queries\10563474\Struc 1.str



chain nodes :  
19 20 21 22 23 26  
ring nodes :  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18  
chain bonds :  
5-19 9-19 10-22 12-20 13-26 14-20 19-21  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18  
14-15 15-16 16-17 17-18  
exact/norm bonds :  
10-22 12-20 13-26 14-20 19-21  
exact bonds :  
5-19 9-19  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18  
14-15 15-16 16-17 17-18

G1:H,F

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS  
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:Atom 26:CLASS

10563474.trn

L1 STRUCTURE uploaded

=> d  
L1 HAS NO ANSWERS  
L1 STR  
\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

Structure attributes must be viewed using STN Express query preparation.

=> l1  
SAMPLE SEARCH INITIATED 10:21:26 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 343 TO ITERATE  
100.0% PROCESSED 343 ITERATIONS 20 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 5749 TO 7971  
PROJECTED ANSWERS: 132 TO 668

L2 20 SEA SSS SAM L1

=> l1 full  
FULL SEARCH INITIATED 10:21:29 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 6839 TO ITERATE

100.0% PROCESSED 6839 ITERATIONS 424 ANSWERS  
SEARCH TIME: 00.00.01

L3 424 SEA SSS FUL L1

=> file caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 178.36 178.57

FILE 'CAPLUS' ENTERED AT 10:21:32 ON 01 AUG 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Aug 2008 VOL 149 ISS 5  
 FILE LAST UPDATED: 30 Jul 2008 (20080730/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.  
 They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> 13  
 L4                  22 L3

=> d ibib abs hitstr 1-22

L4 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 20061605026 CAPLUS  
 DOCUMENT NUMBER: 145:46069  
 TITLE: Preparation of triazole-substituted aminobenzophenones as inhibitors of the production of IL-1 $\beta$  and TNF- $\alpha$  for the treatment of inflammation, ophthalmic diseases and cancer  
 INVENTOR(S): Ottosen, Erik Rytter  
 PATENT ASSIGNEE(S): Leo Pharma A/S, Den.  
 SOURCE: PCT Int. Appl., 101 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006063585	A1	20060622	WO 2005-DK757	20051128
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005316034	A1	20060622	AU 2005-316034	20051128
CA 2590479	A1	20060622	CA 2005-2590479	20051128
EP 1828148	A1	20070905	EP 2005-804019	20051128
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008523115	T	20080703	JP 2007-545836	20051128
MX 200706739	A	20070802	MX 2007-6739	20070606
IN 2007DN04481	A	20070831	IN 2007-DN4481	20070612

NO 2007003574	A 20070710	NO 2007-3574	20070710
KR 2007095945	A 20071001	KR 2007-715959	20070712
CN 101115728	A 20080130	CN 2005-80048038	20070813
PRIORITY APPLN. INFO.:		US 2004-635000P	P 20041213
		DK 2004-1942	A 20041216
		WO 2005-DK757	W 20051128

OTHER SOURCE(S) : MARPAT 145:46069  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB Title compds. I and II [wherein R1 = Me, Cl, Br or MeO; R2 = Cl or Me; R3 = (un)substituted alkyl, alkoxy, alkenyl, etc.; R4 - R8 = H, halo, NH2, etc., with exclusions] and pharmaceutically acceptable salts, solvates, or esters thereof were prepared as inhibitors of the production of IL-1 $\beta$  and TNF- $\alpha$ . For instance, III was obtained by cyclization of 2-(2-azidoethoxy)tetrahydropyran with the corresponding phenylacetylene (preparation given) in the presence of copper(II) sulfate pentahydrate and sodium ascorbate. Hydrolysis of this acetal with TsoH in methanol gave a alc., which was found to be highly potent inhibitors of the production of IL-1 $\beta$  and TNF- $\alpha$  with IC50 of 1.3 nM and 0.5 nM, resp., higher than the six reference compds. The alc. was also found to be a potent p38 MAP kinase inhibitor (no data). Therefore, the invented compds. are useful, e.g., in the treatment of inflammatory, ophthalmic diseases, or cancer.

IT 835625-52-0P 890053-10-8P 890053-11-9P  
 890053-12-0P 890053-13-1P 890053-14-2P  
 890053-15-3P 890053-16-4P 890053-17-5P  
 890053-18-6P 890053-19-7P 890053-21-1P  
 890053-22-2P 890053-23-3P 890053-24-4P  
 890053-27-7P 890053-28-8P 890053-29-9P  
 890053-30-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of triazole-substituted aminobenzophenones as inhibitors of the production of IL-1 $\beta$  and TNF- $\alpha$  for treatment of inflammation, ophthalmic diseases and cancer)


RN 835625-52-0 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl](5-ethynyl-2-methylphenyl)- (CA INDEX NAME)




RN 890053-10-8 CAPLUS  
 CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl](2-methyl-5-

nitrophenyl)- (CA INDEX NAME)




RN 890053-11-9 CAPLUS

CN Methanone, (5-azido-2-methylphenyl)[2-chloro-4-[(4-(trifluoromethyl)phenyl)aminophenyl]- (CA INDEX NAME)




RN 890053-12-0 CAPLUS

CN Methanone, (5-azido-2-methylphenyl)[2-chloro-4-[(2-methylphenyl)amino]phenyl]- (CA INDEX NAME)




RN 890053-13-1 CAPLUS


CN Methanone, (5-azido-2-methylphenyl)[2-chloro-4-[(2-chloro-4-fluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 890053-14-2 CAPLUS  
CN Methanone, (5-bromo-2-methoxyphenyl)[2-chloro-4-[(2,4-difluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 890053-15-3 CAPLUS  
CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl](5-ethynyl-2-methoxyphenyl)- (CA INDEX NAME)




RN 890053-16-4 CAPLUS  
CN Methanone, (5-amino-2-methylphenyl)[2-chloro-4-[(4-fluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 890053-17-5 CAPLUS  
CN Methanone, [2-chloro-4-[(4-fluorophenyl)amino]phenyl](5-ethynyl-2-methylphenyl)- (CA INDEX NAME)




RN 890053-18-6 CAPLUS  
CN Methanone, (5-azido-2-methylphenyl)[2-chloro-4-[(4-fluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 890053-19-7 CAPLUS  
CN Methanone, (5-azido-2-methylphenyl)[2-chloro-4-[(2,4-difluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 890053-21-1 CAPLUS  
CN Methanone, (5-azido-2-methylphenyl)[2-chloro-4-[(4-fluoro-2-methylphenyl)amino]phenyl]- (CA INDEX NAME)




RN 890053-22-2 CAPLUS  
CN Methanone, (5-azido-2-methylphenyl)[2-chloro-4-[(2-methoxyphenyl)amino]phenyl]- (CA INDEX NAME)




RN 890053-23-3 CAPLUS  
CN Methanone, (5-azido-2-methylphenyl)[2-chloro-4-[(4-chloro-2-methylphenyl)amino]phenyl]- (CA INDEX NAME)




RN 890053-24-4 CAPLUS  
CN Methanone, (5-azido-2-methylphenyl)(2-chloro-4-[(4-methoxyphenyl)amino]phenyl)- (CA INDEX NAME)




RN 890053-27-7 CAPLUS  
CN Methanone, (5-azido-2-methylphenyl)(2-chloro-4-[(3-fluorophenyl)amino]phenyl)- (CA INDEX NAME)




RN 890053-28-8 CAPLUS  
CN Methanone, (5-azido-2-methylphenyl)(2-chloro-4-[(3-chlorophenyl)amino]phenyl)- (CA INDEX NAME)



RN 890053-29-9 CAPLUS  
CN Methanone, (5-azido-2-methylphenyl)[2-chloro-4-[(3-methylphenyl)aminophenyl]- (CA INDEX NAME)



RN 890053-30-2 CAPLUS  
CN Methanone, (5-azido-2-methylphenyl)(2-chloro-4-[(3-methoxyphenyl)aminophenyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2006:579261 CAPLUS  
DOCUMENT NUMBER: 145:46068  
TITLE: Preparation of triazole-substituted aminobenzophenones


as inhibitors of the production of IL-1 $\beta$  and TNF- $\alpha$  for the treatment of inflammation, ophthalmic diseases and cancer

INVENTOR(S): Erik, Rytter Ottosen  
 PATENT ASSIGNEE(S): Leo Pharma A/S, Den.  
 SOURCE: U.S. Pat. Appl. Publ., 48 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060128766	A1	20060615	US 2005-292064 US 2004-635000P	20051202 P 20041213
OTHER SOURCE(S):	MARPAT	145:46068		
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


- AB Title compds. I and II [wherein R1 = Me, Cl, Br or MeO; R2 = Cl or Me; R3 = (un)substituted alkyl, alkoxy, alkenyl, etc.; R4 - R8 = H, halo, NH2, etc., with exclusions] and pharmaceutically acceptable salts, solvates, or esters thereof were prepared as inhibitors of the production of IL-1 $\beta$  and TNF- $\alpha$ . For instance, III was obtained by cyclization of 2-(2-azidoethoxy)tetrahydropyran with the corresponding phenylacetylene (preparation given) in the presence of copper(II) sulfate pentahydrate and sodium ascorbate. Hydrolysis of this acetal with TsoH in methanol gave a alc., which was found to be highly potent inhibitors of the production of IL-1 $\beta$  and TNF- $\alpha$  with IC50 of 1.3 nM and 0.5 nM, resp., higher than the six reference compds. The alc. was also found to be a potent p38 MAP kinase inhibitor (no data). Therefore, the invented compds. are useful, e.g., in the treatment of inflammatory, ophthalmic diseases, or cancer.
- IT 835625-52-0P, [2-Chloro-4-(2,4-difluorophenylamino)phenyl](5-ethynyl-2-methylphenyl)methanone 890053-10-8P  
 890053-11-9P 890053-12-0P 890053-13-1P  
 890053-14-2P 890053-15-3P 890053-16-4P  
 890053-17-5P 890053-18-6P 890053-19-7P  
 890053-21-1P 890053-22-2P 890053-23-3P  
 890053-24-4P 890053-27-7P 890053-28-8P  
 890053-29-9P 890053-30-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of triazole-substituted aminobenzophenones as inhibitors of the production of IL-1 $\beta$  and TNF- $\alpha$  for treatment of inflammation, ophthalmic diseases and cancer)
- RN 835625-52-0 CAPLUS
- CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl](5-ethynyl-2-methylphenyl)- (CA INDEX NAME)




RN 890053-10-8 CAPLUS  
CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl](2-methyl-5-nitrophenyl)- (CA INDEX NAME)




RN 890053-11-9 CAPLUS  
CN Methanone, (5-azido-2-methylphenyl)[2-chloro-4-[(4-(trifluoromethyl)phenyl)amino]phenyl]- (CA INDEX NAME)




RN 890053-12-0 CAPLUS  
CN Methanone, (5-azido-2-methylphenyl)[2-chloro-4-[(2-methylphenyl)amino]phenyl]- (CA INDEX NAME)




RN 890053-13-1 CAPLUS  
CN Methanone, (5-azido-2-methylphenyl)[2-chloro-4-[(2-chloro-4-fluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 890053-14-2 CAPLUS  
CN Methanone, (5-bromo-2-methoxyphenyl)[2-chloro-4-[(2,4-difluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 890053-15-3 CAPLUS  
CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl](5-ethynyl-2-methoxyphenyl)- (CA INDEX NAME)




RN 890053-16-4 CAPLUS  
CN Methanone, (5-amino-2-methylphenyl)[2-chloro-4-[(4-fluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 890053-17-5 CAPLUS  
CN Methanone, [2-chloro-4-[(4-fluorophenyl)amino]phenyl](5-ethynyl-2-methylphenyl)- (CA INDEX NAME)




RN 890053-18-6 CAPLUS  
CN Methanone, (5-azido-2-methylphenyl)[2-chloro-4-[(4-fluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 890053-19-7 CAPLUS  
CN Methanone, (5-azido-2-methylphenyl)[2-chloro-4-[(2,4-difluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 890053-21-1 CAPLUS  
CN Methanone, (5-azido-2-methylphenyl)[2-chloro-4-[(4-fluoro-2-methylphenyl)amino]phenyl]- (CA INDEX NAME)




RN 890053-22-2 CAPLUS  
CN Methanone, (5-azido-2-methylphenyl)[2-chloro-4-[(2-methoxyphenyl)amino]phenyl]- (CA INDEX NAME)




RN 890053-23-3 CAPLUS  
CN Methanone, (5-azido-2-methylphenyl)(2-chloro-4-[(4-chloro-2-methoxyphenyl)amino]phenyl)- (CA INDEX NAME)




RN 890053-24-4 CAPLUS  
CN Methanone, (5-azido-2-methylphenyl)(2-chloro-4-[(4-methoxyphenyl)amino]phenyl)- (CA INDEX NAME)




RN 890053-27-7 CAPLUS  
CN Methanone, (5-azido-2-methylphenyl)(2-chloro-4-[(3-fluorophenyl)amino]phenyl)- (CA INDEX NAME)




RN 890053-28-8 CAPLUS  
CN Methanone, (5-azido-2-methylphenyl)(2-chloro-4-[(3-chlorophenyl)amino]phenyl)- (CA INDEX NAME)



RN 890053-29-9 CAPLUS  
CN Methanone, (5-azido-2-methylphenyl)(2-chloro-4-[(3-methylphenyl)amino]phenyl)- (CA INDEX NAME)





RN 890053-30-2 CAPLUS  
CN Methanone, (5-azido-2-methylphenyl)(2-chloro-4-[(3-methoxyphenyl)amino]phenyl)- (CA INDEX NAME)



L4 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2005:99452 CAPLUS  
 DOCUMENT NUMBER: 1421176548  
 TITLE: Preparation of novel aminobenzophenones as inhibitors of interleukin IL-1 $\beta$  and tumor necrosis factor TNF- $\alpha$  production and their use in the treatment of inflammatory diseases and conditions  
 INVENTOR(S): Ottosen, Erik Rytter; Horneman, Anne Marie; Liang, Xifu; Schou, Soren Christian; Havez, Sophie Elisabeth; Sabroe, Thomas Peter  
 PATENT ASSIGNEE(S): Leo Pharma A/S, Den.  
 SOURCE: PCT Int. Appl., 247 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009940	A1	20050203	WO 2004-DK490	20040709
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW, BN, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004259264	A1	20050203	AU 2004-259264	20040709
CA 2530302	A1	20050203	CA 2004-2530302	20040709
EP 1658263	A1	20060524	EP 2004-738987	20040709
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1826310	A	20060830	CN 2004-80021378	20040709
BR 2004012893	A	20061003	BR 2004-12893	20040709
JP 2006528597	T	20061221	JP 2006-520673	20040709
US 20060166990	A1	20060727	US 2006-563474	20060105
NO 2006000230	A	20060116	NO 2006-230	20060116

MX 2006PA00708 IN 2006DN00410 PRIORITY APPLN. INFO.:	A 20060419 A 20070831	MX 2006-PA708 IN 2006-DN410 US 2003-489488P WO 2004-DK490	20060118 20060123 P 20030724 W 20040709
OTHER SOURCE(S): GI	CASREACT 142:176548; MARPAT 142:176548		



**AB** Title compds. I [wherein R1 = halo, OH, SH, CF3, alk(en/yn)yl, alkoxy, CN, CONH2, NO2, etc.; R2 = H, halo, PH, NO2, CONH2, OH, SH, alk(en/yn)yl, etc.; R3 = one or more, independently H, halo, OH, SH, CN, CO2H, NO2, alkoxy carbonyl, etc.; R4 = H, halo, NO2, etc.; R5, R6 = independently H, CO2H, CONHOH, CONHNH2, (un)substituted alk(en/yn)yl, alkylamino, etc.; with provisos; and their pharmaceutically acceptable salts, solvates and esters] were prepared as inhibitors of interleukin IL-1 $\beta$  and tumor necrosis factor TNF- $\alpha$  production for treating inflammation and related diseases. For example, II was prepared, in 6 steps, from 3-iodo-4-methylbenzoic acid Me ester, 2-chloro-4-nitrobenzoyl chloride, and 1-iodo-2-nitrobenzene. II displayed potent inhibitory activity against p38 $\alpha$  MAP kinase with IC50 of 2 nM and inhibited production of IL-1 $\beta$  and TNF- $\alpha$  in vitro with IC50 values of 4.0 nM and 0.6 nM. Thus, I are useful in the treatment of inflammatory, ophthalmic diseases or cancer.


**IT** 835622-86-1P, 3-[4-(2-Aminophenylamino)-2-chlorobenzoyl]-N-(2-hydroxyethyl)-4-methylbenzamide 835622-90-7P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzoic acid 835622-92-9P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2-hydroxyethyl)-4-methylbenzamide 835622-94-1P, 3-[4-(2-Aminophenylamino)-2-chlorobenzoyl]-4-methylbenzoic acid 835622-98-5P, 3-[2-Chloro-4-(4-chloro-2-fluorophenylamino)benzoyl]-4-methylbenzoic acid 835623-01-3P, {[2-[3-[2-Chloro-4-(4-chloro-

2-fluorophenylamino)benzoyl]-4-methylbenzoylamino]acetyl]amino]acetic acid ethyl ester 835623-13-7P, 2-Methylacrylic acid  
 2-[3-[2-chloro-4-(4-chloro-2-fluorophenylamino)benzoyl]-4-methylbenzoylamino]ethyl ester 835623-16-0P,  
 [2-[3-[2-Chloro-4-(4-chloro-2-fluorophenylamino)benzoyl]-4-methylbenzoylamino]ethyl]carbamic acid tert-butyl ester 835623-19-3P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methoxybenzoic acid 835623-94-4P, [4-(2-Aminophenylamino)-2-chlorophenyl]-[2-methyl-4-[2-[(tetrahydropyran-2-yl)oxylethoxy]phenyl]methanone 835623-95-5P,  
 [4-(2-Aminophenylamino)-2-chlorophenyl]-[4-(2-hydroxyethoxy)-2-methylphenyl]methanone 835623-96-6P, [4-(2-Amino-4-bromophenylamino)-2-chlorophenyl]-[2-methyl-4-[2-[(tetrahydropyran-2-yl)oxylethoxy]phenyl]methanone 835624-03-8P,  
 [4-(4-Bromo-2-methylphenylamino)-2-chlorophenyl]-[2-methyl-4-[2-[(tetrahydropyran-2-yl)oxylethoxy]phenyl]methanone 835624-04-9P,  
 [4-(4-Bromo-2-methylphenylamino)-2-chlorophenyl]-[4-(2-hydroxyethoxy)-2-methylphenyl]methanone 835624-05-0P, [4-(2-Azidoethoxy)-2-methylphenyl]-[4-(4-bromo-2-methylphenylamino)-2-chlorophenyl]methanone 835624-07-2P, [4-(2-Bromophenylamino)-2-chlorophenyl]-[2-methyl-4-[2-[(tetrahydropyran-2-yl)oxylethoxy]phenyl]methanone 835624-08-3P,  
 , [4-[2-(3-Amino-1-propenyl)phenyl]amino]-2-chlorophenyl]-[2-methyl-4-[2-[(tetrahydropyran-2-yl)oxylethoxy]phenyl]methanone 835624-11-8P,  
 1-[5-Bromo-2-[(3-chloro-4-[2-methyl-4-[2-(tetrahydropyran-2-yloxy)ethoxy]benzoyl]phenyl)amino]phenyl]-3-ethylurea 835624-14-1P  
 , 1-[5-Bromo-2-[(3-chloro-4-[2-methyl-4-[2-(tetrahydropyran-2-yloxy)ethoxy]benzoyl]phenyl)amino]phenyl]-3-(2-hydroxyethyl)urea 835624-35-6P, N-[3-(2-Chloro-4-(2,4-difluorophenylamino)benzoyl)-4-methylphenyl]-3-methylsulfanylpropionamide 835624-46-9P,  
 2-Methylacrylic acid 2-[3-[3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]ureido]ethyl ester 835624-87-8P,  
 [4-(4-Fluoro-2-methylphenylamino)-2-nitropropoxy]-2-methylphenyl]methanone 835624-89-0P, [5-[2,2-Dimethyl-  
 [1,3]dioxolan-4-yl)methoxy]-2-methylphenyl]-[4-(4-fluoro-2-methylphenylamino)-2-nitrophenyl]methanone 835624-90-3P,  
 [5-(2,3-Dihydroxypropoxy)-2-methylphenyl]-[4-(4-fluoro-2-methylphenylamino)-2-nitrophenyl]methanone 835624-92-5P, [4-(4-Fluoro-2-methylphenylamino)-2-nitrophenyl]-[2-methyl-5-[2-(morpholin-4-yl)ethoxy]phenyl]methanone 835624-95-8P, [4-(2,4-Difluorophenylamino)-2-nitrophenyl]-[5-(3-hydroxypropoxy)-2-methylphenyl]methanone 835624-99-2P, [4-(2,4-Difluorophenylamino)-2-nitrophenyl]-[5-[2,2-dimethyl-[1,3]dioxolan-4-yl)methoxy]-2-methylphenyl]methanone 835625-00-8P,  
 [4-(2,4-Difluorophenylamino)-2-nitrophenyl]-[5-(2,3-dihydroxypropoxy)-2-methylphenyl]methanone 835625-03-1P, [2-Chloro-4-(2,4-difluorophenylamino)phenyl]-[5-[2,2-dimethyl-[1,3]dioxolan-4-yl)methoxy]-2-fluorophenyl]methanone 835625-08-6P, [2-Chloro-4-(4-chloro-2-methylphenylamino)phenyl]-[5-[2,2-dimethyl-[1,3]dioxolan-4-yl)methoxy]-2-fluorophenyl]methanone 835625-20-2P, [2-Chloro-4-(2,4-difluorophenylamino)phenyl]-[5-hydroxymethyl-2-methylphenyl]methanone 835625-21-3P, [2-Chloro-4-(2,4-difluorophenylamino)phenyl]-[5-hydroxymethyl-2-methylphenyl]methanone 835625-22-4P,  
 (5-Azidomethyl-2-methylphenyl)-[2-chloro-4-(2,4-difluorophenylamino)phenyl]-[5-hydroxymethyl-2-methoxyphenyl]methanone 835625-24-6P,  
 [2-Chloro-4-(2,4-difluorophenylamino)phenyl]-[5-hydroxymethyl-2-methoxyphenyl]methanone 835625-38-2P, 4-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzoylamino]thiophene-3-carboxylic

acid methyl ester 835625-41-7P, 2-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzoylamino]benzoic acid methyl ester 835625-54-2P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzoic hydrazide 835625-55-3P, 1-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzoyl]-4-ethyl-3-thiosemicarbazide  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(p38 $\alpha$  MAP kinase inhibitor; preparation of aminobenzophenones as inhibitors of IL-1 $\beta$  and TNF- $\alpha$  production for treating inflammatory diseases or conditions)


RN 835622-86-1 CAPLUS

CN Benzamide, 3-[4-[(2-aminophenyl)amino]-2-chlorobenzoyl]-N-(2-hydroxyethyl)-4-methyl- (CA INDEX NAME)




RN 835622-90-7 CAPLUS

CN Benzoic acid, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl- (CA INDEX NAME)




RN 835622-92-9 CAPLUS


CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2-hydroxyethyl)-4-methyl- (CA INDEX NAME)




RN 835622-94-1 CAPLUS  
CN Benzoic acid, 3-[4-[(2-aminophenyl)amino]-2-chlorobenzoyl]-4-methyl- (CA INDEX NAME)



RN 835622-98-5 CAPLUS  
CN Benzoic acid, 3-[2-chloro-4-[(4-chloro-2-fluorophenyl)amino]benzoyl]-4-methyl- (CA INDEX NAME)




RN 835623-01-3 CAPLUS  
CN Glycine, N-[3-[2-chloro-4-[(4-chloro-2-fluorophenyl)amino]benzoyl]-4-methylbenzoyl]glycyl-, ethyl ester (CA INDEX NAME)




RN 835623-13-7 CAPLUS

CN 2-Propenoic acid, 2-methyl-, 2-[[3-[2-chloro-4-[(4-chloro-2-fluorophenyl)amino]benzoyl]-4-methylbenzoyl]amino]ethyl ester (CA INDEX NAME)




RN 835623-16-0 CAPLUS

CN Carbamic acid, [2-[3-[2-chloro-4-[(4-chloro-2-fluorophenyl)amino]benzoyl]-4-methylbenzoyl]aminoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 835623-19-3 CAPLUS

CN Benzoic acid, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methoxy- (CA INDEX NAME)




RN 835623-94-4 CAPLUS

CN Methanone, [4-[(2-aminophenyl)amino]-2-chlorophenyl][2-methyl-4-[(2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy)phenyl]- (CA INDEX NAME)




RN 835623-95-5 CAPLUS

CN Methanone, [4-[(2-aminophenyl)amino]-2-chlorophenyl][4-[(2-hydroxyethoxy)-2-methylphenyl]- (CA INDEX NAME)




RN 835623-96-6 CAPLUS


CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl][2-methyl-4-[(2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy)phenyl]- (CA INDEX NAME)




RN 835624-03-8 CAPLUS  
CN Methanone, [4-[(4-bromo-2-methylphenyl)amino]-2-chlorophenyl][2-methyl-4-[2-{(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]phenyl]- (CA INDEX NAME)



RN 835624-04-9 CAPLUS  
CN Methanone, [4-[(4-bromo-2-methylphenyl)amino]-2-chlorophenyl][4-(2-hydroxyethoxy)-2-methylphenyl]- (CA INDEX NAME)




RN 835624-05-0 CAPLUS  
CN Methanone, [4-(2-azidoethoxy)-2-methylphenyl][4-[(4-bromo-2-methylphenyl)amino]-2-chlorophenyl]- (CA INDEX NAME)




RN 835624-07-2 CAPLUS

CN Methanone, [4-[(2-bromophenyl)amino]-2-chlorophenyl][2-methyl-4-[2-(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]phenyl- (CA INDEX NAME)




RN 835624-08-3 CAPLUS

CN Methanone, [4-[(2-(3-amino-1-propenyl)phenyl)amino]-2-chlorophenyl][2-methyl-4-[2-(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]phenyl- (CA INDEX NAME)




RN 835624-11-8 CAPLUS

CN Urea, N-[5-bromo-2-[(3-chloro-4-[2-methyl-4-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]benzoyl]phenyl]amino]phenyl-N'-ethyl- (CA INDEX NAME)




RN 835624-14-1 CAPLUS

CN Urea, N-[5-bromo-2-[(3-chloro-4-[2-methyl-4-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]benzoyl]phenyl]amino]phenyl]- (CA INDEX NAME)




RN 835624-35-6 CAPLUS

CN Propanamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-3-(methylthio)- (CA INDEX NAME)




RN 835624-46-9 CAPLUS

CN 2-Propenoic acid, 2-methyl-, 2-[[[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]amino]carbonyl]amino]ethyl ester (CA INDEX NAME)




RN 835624-87-8 CAPLUS

CN Methanone, [4-[(4-fluoro-2-methylphenyl)amino]-2-nitrophenyl][5-(3-hydroxypropoxy)-2-methylphenyl]- (CA INDEX NAME)




RN 835624-89-0 CAPLUS

CN Methanone, [5-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-2-methylphenyl][4-[(4-fluoro-2-methylphenyl)amino]-2-nitrophenyl]- (CA INDEX NAME)




RN 835624-90-3 CAPLUS


CN Methanone, [5-(2,3-dihydroxypropoxy)-2-methylphenyl][4-[(4-fluoro-2-methylphenyl)amino]-2-nitrophenyl]- (CA INDEX NAME)




RN 835624-92-5 CAPLUS  
CN Methanone, [4-[(4-fluoro-2-methylphenyl)amino]-2-nitrophenyl][2-methyl-5-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)




RN 835624-95-8 CAPLUS  
CN Methanone, [4-[(2,4-difluorophenyl)amino]-2-nitrophenyl][5-[(3-hydroxypropoxy)-2-methylphenyl]- (CA INDEX NAME)




RN 835624-99-2 CAPLUS  
CN Methanone, [4-[(2,4-difluorophenyl)amino]-2-nitrophenyl][5-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-2-methylphenyl]- (CA INDEX NAME)




RN 835625-00-8 CAPLUS  
CN Methanone, [4-[(2,4-difluorophenyl)amino]-2-nitrophenyl][5-(2,3-dihydroxypropoxy)-2-methylphenyl]- (CA INDEX NAME)




RN 835625-03-1 CAPLUS  
CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-2-fluorophenyl]- (CA INDEX NAME)




RN 835625-08-6 CAPLUS  
CN Methanone, [2-chloro-4-[(4-chloro-2-methylphenyl)amino]phenyl][5-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-2-fluorophenyl]- (CA INDEX NAME)




RN 835625-20-2 CAPLUS  
CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-(hydroxymethyl)-2-methylphenyl]- (CA INDEX NAME)




RN 835625-21-3 CAPLUS  
CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-(chloromethyl)-2-methylphenyl]- (CA INDEX NAME)




RN 835625-22-4 CAPLUS  
CN Methanone, [5-(azidomethyl)-2-methylphenyl][2-chloro-4-[(2,4-difluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 835625-24-6 CAPLUS  
CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl]-[5-(hydroxymethyl)-2-methoxyphenyl]- (CA INDEX NAME)




RN 835625-38-2 CAPLUS  
CN 3-Thiophene carboxylic acid, 4-[(3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylbenzoyl)amino]-, methyl ester (CA INDEX NAME)




RN 835625-41-7 CAPLUS  
CN Benzoic acid, 2-[(3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylbenzoyl)amino]-, methyl ester (CA INDEX NAME)



RN 835625-54-2 CAPLUS  
CN Benzoic acid, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-,  
hydrazide (CA INDEX NAME)



RN 835625-55-3 CAPLUS  
CN Benzoic acid, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-,  
2-[(ethylamino)thioxomethyl]hydrazide (CA INDEX NAME)



IT 835622-75-8P, [2-Chloro-4-(4-fluoro-2-methylphenylamino)phenyl][2-methyl-5-[(methylpiperazin-1-yl)carbonyl]phenyl]methanone 835622-76-9P,  
, [2-Chloro-4-(4-fluoro-2-methylphenylamino)phenyl][2-methyl-5-[(4-methylpiperazin-1-yl)carbonyl]phenyl]methanone 835622-77-0P,  
3-[2-Chloro-4-(4-fluoro-2-methylphenylamino)benzoyl]-N-methoxy-4-methyl-N-methylbenzamide 835622-78-1P, 3-[2-Chloro-4-(4-fluoro-2-methylphenylamino)benzoyl]-4-methyl-N-[(tetrahydrofuran-2-yl)methyl]benzamide 835622-79-2P, 3-[2-Chloro-4-(4-fluoro-2-methylphenylamino)benzoyl]-4-methyl-N-methyl-N-[(tetrahydrofuran-2-

y1)methyl]benzamide 835622-80-5P, 3-[2-Chloro-4-(4-fluoro-2-methylphenylamino)benzoyl]-N-(2-methoxyethyl)-4-methylbenzamide 835622-81-6P, 3-[2-Chloro-4-(4-fluoro-2-methylphenylamino)benzoyl]-4-methyl-N-[3-(morpholin-4-yl)propyl]benzamide 835622-82-7P, [2-Chloro-4-(4-fluoro-2-methylphenylamino)phenyl]15-[(4-(2-methoxyethyl)piperazin-1-yl)carbonyl]-2-methylphenyl]methanone 835622-83-8P, 3-[2-Chloro-4-(4-fluoro-2-methylphenylamino)benzoyl]-4-methyl-N-[(pyridin-2-yl)methyl]benzamide 835622-85-0P, 3-[2-Chloro-4-(4-fluoro-2-methylphenylamino)benzoyl]-4-methyl-N-[(pyridin-2-yl)methyl]benzamide 835622-87-2P, 3-[4-(2-Amino-4-bromophenylamino)-2-chlorobenzoyl]-N-(2-hydroxyethyl)-4-methylbenzamide 835622-88-3P, 3-[4-(4-Bromo-2-methylphenylamino)-2-chlorobenzoyl]-4-methylbenzoic acid 835622-89-4P, 3-[4-(4-Bromo-2-methylphenylamino)-2-chlorobenzoyl]-N-(2-hydroxyethyl)-4-methylbenzamide 835622-91-8P, 2-Methylacrylic acid 2-[3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzylamino]ethyl ester 835622-93-0P, 3-[4-(2-Aminophenylamino)-2-chlorobenzoyl]-N-(2-methoxyethyl)-4-methylbenzamide 835622-95-2P, 3-[4-(2-Aminophenylamino)-2-chlorobenzoyl]-N-ethyl-4-methylbenzamide 835622-96-3P, 3-[4-(2-Aminophenylamino)-2-chlorobenzoyl]-N-(3-hydroxypyropyl)-4-methylbenzamide 835622-97-4P, 3-[2-Chloro-4-(4-fluoro-2-methylphenylamino)benzoyl]-N-(2-hydroxyethyl)-4-methylbenzamide 835622-99-6P, 3-[2-Chloro-4-(4-chloro-2-fluorophenylamino)benzoyl]-N-(2-hydroxyethyl)-4-methylbenzamide 835623-00-2P, 3-[2-Chloro-4-(4-chloro-2-fluorophenylamino)benzoyl]-4-methyl-N-methylbenzamide 835623-02-4P, [3-[2-Chloro-4-(4-chloro-2-fluorophenylamino)benzoyl]-4-methylbenzylamino]acetic acid ethyl ester 835623-03-5P, 3-[2-Chloro-4-(4-chloro-2-fluorophenylamino)benzoyl]-N-(2-methoxyethyl)-4-methylbenzamide 835623-04-6P, 3-[2-Chloro-4-(4-chloro-2-fluorophenylamino)benzoyl]-N-cyclohexyl-4-methylbenzamide 835623-05-7P, 3-[2-Chloro-4-(4-chloro-2-fluorophenylamino)benzoyl]-N-ethyl-4-methylbenzamide 835623-06-8P, 3-[2-Chloro-4-(4-chloro-2-fluorophenylamino)benzoyl]-N-(6-hydroxyhexyl)-4-methylbenzamide 835623-07-9P, 3-[2-Chloro-4-(4-chloro-2-fluorophenylamino)benzoyl]-N-isopropyl-4-methylbenzamide 835623-08-0P, 3-[2-Chloro-4-(4-chloro-2-fluorophenylamino)benzoyl]-N-isobutyl-4-methylbenzamide 835623-09-1P, 3-[2-Chloro-4-(4-chloro-2-fluorophenylamino)benzoyl]-N-(2-dimethylpropyl)-4-methylbenzamide 835623-10-4P, 3-[2-Chloro-4-(4-chloro-2-fluorophenylamino)benzoyl]-N-(3-methoxypropyl)-4-methylbenzamide 835623-11-5P, 3-[2-Chloro-4-(4-chloro-2-fluorophenylamino)benzoyl]-4-methyl-N-[3-(2-oxopyrrolidin-1-yl)propyl]benzamide 835623-12-6P, 3-[2-Chloro-4-(4-chloro-2-fluorophenylamino)benzoyl]-N-(2-dimethylaminoethyl)-4-methylbenzamide 835623-14-8P, 3-[2-Chloro-4-(4-chloro-2-fluorophenylamino)benzoyl]-cis-N-(4-hydroxycyclohexyl)-4-methylbenzamide 835623-15-9P, 3-[2-Chloro-4-(4-chloro-2-fluorophenylamino)benzoyl]-trans-N-(4-hydroxycyclohexyl)-4-methylbenzamide 835623-17-1P, N-(2-Aminothyl)-3-[2-chloro-4-(4-chloro-2-fluorophenylamino)benzoyl]-4-methylbenzamide 835623-18-2P, [(2-[3-[2-Chloro-4-(4-chloro-2-fluorophenylamino)benzoyl]-4-methylbenzylamino]acetyl]amino]acetic acid 835623-20-6P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2-hydroxyethyl)-4-methoxybenzamide 835623-21-7P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2,2-difluoroethyl)-4-methoxybenzamide 835623-22-8P, 3-[2-Chloro-4-(2,4-

difluorophenylamino)benzoyl]-N-(2-fluoroethyl)-4-methoxybenzamide 835623-23-9P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2,3-dihydroxypropyl)-4-methoxybenzamide 835623-24-0P, N-(Carbamoylmethyl)-3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methoxybenzamide 835623-25-1P, N-(Carbamoylmethyl)-3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzamide 835623-26-2P , N-Benzyl-3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methoxybenzamide 835623-27-3P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2-fluoroethyl)-4-methylbenzamide 835623-28-4P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methyl-N-(2,2,2-trifluoroethyl)benzamide 835623-29-5P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-ethyl-4-methylbenzamide 835623-30-6P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-cyclohexylmethyl-4-methylbenzamide 835623-31-9P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2-hydroxypropyl)-4-methylbenzamide 835623-32-0P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2,3-dihydroxypropyl)-4-methylbenzamide 835623-33-1P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(1-hydroxymethylpropyl)-4-methylbenzamide 835623-34-2P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methyl-N-(2,2,3,3,3-pentafluoropropyl)benzamide 835623-35-3P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(3-hydroxypropyl)-4-methylbenzamide 835623-36-4P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2-hydroxy-1,1-dimethylethyl)-4-methylbenzamide 835623-37-5P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2-hydroxy-1-hydroxymethyl-1-methylethyl)-4-methylbenzamide 835623-38-6P, [3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzoyl]acetic acid ethyl ester 835623-39-7P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(4-hydroxybutyl)-4-methylbenzamide 835623-40-0P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(3-hydroxy-1,1-dimethylbutyl)-4-methylbenzamide 835623-41-1P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methyl-N-(3-phenylpropyl)benzamide 835623-42-2P, (R)-3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(1-hydroxymethyl-3-methylbutyl)-4-methylbenzamide 835623-44-4P , 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-isopropyl-4-methylbenzamide 835623-45-5P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-cyclohexyl-4-methylbenzamide 835623-46-6P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2,2-difluoroethyl)-4-methylbenzamide 835623-47-7P, 5-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzoylamino]-4-oxopentanoic acid methyl ester 835623-48-8P, N-[1-(Carbamoylcarbamoyl)methyl]-3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzamide 835623-49-9P, [[2-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzoylamino]acetyl]amino]acetic acid ethyl ester 835623-50-2P, N-Allyl-3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzamide 835623-51-3P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methyl-N-(2-sulfamoylethyl)benzamide 835623-52-4P, N-(2-Acetylaminooethyl)-3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzamide 835623-53-5P, 3-[2-Chloro-4-(2,6-difluorophenylamino)benzoyl]-4-methoxybenzoic acid 835623-54-6P, 3-[2-Chloro-4-(2,6-difluorophenylamino)benzoyl]-N-(2-hydroxyethyl)-4-methoxybenzamide 835623-55-7P, 3-[2-Chloro-4-(2,6-difluorophenylamino)benzoyl]-N-(2-fluoroethyl)-4-methoxybenzamide 835623-56-8P, 3-[2-Chloro-4-(2,6-difluorophenylamino)benzoyl]-N-(2,3-dihydroxypropyl)-4-

methoxybenzamide 835623-57-9P, 3-[2-Chloro-4-(2,6-difluorophenylamino)benzoyl]-N-(3-hydroxypropyl)-4-methoxybenzamide 835623-58-0P, 3-[2-Chloro-4-(2,6-difluorophenylamino)benzoyl]-4-methoxy-N-phenethylbenzamide 835623-59-1P, 3-[2-Chloro-4-(2,6-difluorophenylamino)benzoyl]-N-(2-hydroxy-1,1-dimethylethyl)-4-methoxybenzamide 835623-60-4P, 3-[2-Chloro-4-(2,6-difluorophenylamino)benzoyl]-N-(2-hydroxy-1,1-dimethylethyl)-4-methoxybenzamide 835623-61-5P, 3-[2-Chloro-4-(2,6-difluorophenylamino)benzoyl]-N-(2-hydroxy-1-hydroxymethyl-1-methylethyl)-4-methoxybenzamide 835623-62-6P, 3-[2-Chloro-4-(2,6-difluorophenylamino)benzoyl]-N-(2-hydroxyethyl)-4-methoxy-N-methylbenzamide 835623-63-7P, [(3-[2-Chloro-4-(2,6-difluorophenylamino)benzoyl]-4-methoxybenzoyl]amino)acetic acid ethyl ester 835623-64-8P, [[2-[(3-[2-Chloro-4-(2,6-difluorophenylamino)benzoyl]-4-methoxybenzoyl]amino)acetyl]amino]acetic acid ethyl ester 835623-65-9P, 3-[2-Chloro-4-(2,6-difluorophenylamino)benzoyl]-N,N-bis(2-hydroxyethyl)-4-methoxybenzamide 835623-66-0P, 3-[2-Chloro-4-(2,6-difluorophenylamino)benzoyl]-4-methoxy-N,N-bis(2-hydroxyethylbenzoyl)benzamide 835623-67-1P, 3-[2-Chloro-4-(3-fluoro-2-methylphenylamino)benzoyl]-4-methylbenzoic acid 835623-68-2P, 3-[2-Chloro-4-(3-fluoro-2-methylphenylamino)benzoyl]-N-(2-hydroxyethyl)-4-methylbenzamide 835623-69-3P, 3-[2-Chloro-4-(3-fluoro-2-methylphenylamino)benzoyl]-4-methyl-N-(2,2,2-trifluoroethyl)benzamide 835623-70-6P, 3-[2-Chloro-4-(2-chloro-4-fluorophenylamino)benzoyl]-4-methylbenzoic acid 835623-71-7P, 3-[2-Chloro-4-(2-chloro-4-fluorophenylamino)benzoyl]-N-(2-hydroxyethyl)-4-methylbenzamide 835623-72-8P, 3-[2-Chloro-4-(2-chloro-4-fluorophenylamino)benzoyl]-4-methyl-N-(2,2,2-trifluoroethyl)benzamide 835623-73-9P, 3-[2-Chloro-4-(4-fluorophenylamino)benzoyl]-N-(2-hydroxyethyl)-4-methylbenzamide 835623-74-0P, 3-(2-Chloro-4-phenylaminobenzoyl)-N-(2-hydroxyethyl)-4-methylbenzamide 835623-75-1P, 3-[2-Chloro-4-(3,5-difluorophenylamino)benzoyl]-N-(2-hydroxyethyl)-4-methylbenzamide 835623-76-2P, 3-[2-Chloro-4-(3-fluorophenylamino)benzoyl]-N-(2-hydroxyethyl)-4-methylbenzamide 835623-77-3P, 3-[2-Chloro-4-(4-fluorophenylamino)benzoyl]-N-(2-hydroxyethyl)-4-methoxybenzamide 835623-78-4P, 3-(2-Chloro-4-phenylaminobenzoyl)-N-(2-hydroxyethyl)-4-methoxybenzamide 835623-79-5P, 3-[2-Chloro-4-(4-fluorophenylamino)benzoyl]-N-(2,2-difluoroethyl)-4-methoxybenzamide 835623-80-6P, 3-[2-Chloro-4-(4-fluorophenylamino)benzoyl]-N-(2-fluoroethyl)-4-methoxybenzamide 835623-81-9P, 3-[2-Chloro-4-(4-fluorophenylamino)benzoyl]-N-(2,3-dihydroxypropyl)-4-methoxybenzamide 835623-82-0P, N-(Carbamoylmethyl)-3-[2-chloro-4-(4-fluorophenylamino)benzoyl]-4-methoxybenzamide 835623-83-1P, 3-(2-Chloro-4-phenylaminobenzoyl)-N-(2,2-difluoroethyl)-4-methoxybenzamide 835623-84-2P, 3-(2-Chloro-4-phenylaminobenzoyl)-N-(2-fluoroethyl)-4-methoxybenzamide 835623-85-3P, 3-(2-Chloro-4-phenylaminobenzoyl)-N-(2,3-dihydroxypropyl)-4-methoxybenzamide 835623-86-4P, N-(Carbamoylmethyl)-3-(2-chloro-4-phenylaminobenzoyl)-4-methoxybenzamide 835623-87-5P, 4-Chloro-3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2-hydroxyethyl)benzamide 835623-88-6P, {2-[(3-Chloro-4-[5-(2-hydroxyethylcarbamoyl)-2-methylbenzoyl]phenyl)amino]phenyl}carbamic acid ethyl ester 835623-89-7P, 3-[2-Chloro-4-[1-(2-propionylaminophenyl)amino]benzoyl]-N-(2-hydroxyethyl)-4-methylbenzamide 835623-90-0P, 3-[4-(2-Acetylaminophenyl)amino]-2-chlorobenzoyl]-N-(2-hydroxyethyl)-4-


methylbenzamide 835623-91-1P, N-[2-[(3-Chloro-4-[5-(2-hydroxyethylcarbamoyl)-2-methylbenzoyl]phenyl)amino]phenyl]succinamic acid 835623-92-2P, 3-[2-Chloro-4-[2-[3-(2-hydroxyethyl)ureido]phenyl]amino]benzoyl]-N-(2-hydroxyethyl)-4-methylbenzamide 835623-93-3P, [2-Chloro-4-(4-fluoro-2-methylphenylamino)phenyl][2-methyl-4-[(morpholin-4-yl)carbonyl]phenyl]methanone 835623-97-7P, [4-(2-Amino-4-bromophenylamino)-2-chlorophenyl][4-(2-hydroxyethoxy)-2-methylphenyl]methanone 835623-98-8P, [4-(2-Amino-4-bromophenylamino)-2-chlorophenyl][2-methyl-4-[3-[(tetrahydropyran-2-yl)oxyl]propoxy]phenyl]methanone 835623-99-9P, [4-(2-Amino-4-bromophenylamino)-2-chlorophenyl][4-(3-hydroxypropoxy)-2-methylphenyl]methanone 835624-00-5P, [4-(2-Amino-4-bromophenylamino)-2-chlorophenyl][4-(2-fluoroethoxy)-2-methylphenyl]methanone 835624-01-6P, [4-(4-Bromo-2-methylphenylamino)-2-chlorophenyl][4-(2-fluoroethoxy)-2-methylphenyl]methanone 835624-02-7P, [4-(2-Amino-4-bromophenylamino)-2-chlorophenyl][4-(2-methoxyethoxy)-2-methylphenyl]methanone 835624-06-1P, [4-(2-Aminoethoxy)-2-methylphenyl][4-(4-bromo-2-methylphenylamino)-2-chlorophenyl]methanone 835624-09-4P, [4-[(3-Amino-1-propenyl)phenyl]amino]-2-chlorophenyl][4-(2-hydroxyethoxy)-2-methylphenyl]methanone 835624-10-7P, 1-[2-[(3-Chloro-4-[4-(2-hydroxyethoxy)-2-methylbenzoyl]phenyl)amino]phenyl]-3-ethylurea 835624-12-9P, 1-[5-Bromo-2-[[3-chloro-4-[4-(2-hydroxyethoxy)-2-methylbenzoyl]phenyl]amino]phenyl]-3-ethylurea 835624-13-0P, 1-[5-Bromo-2-[[3-chloro-4-[2-methyl-4-[2-(tetrahydropyran-2-yloxy)ethoxy]benzoyl]phenyl]amino]phenyl]-3-cyclohexylurea 835624-15-2P, 1-[5-Bromo-2-[[3-chloro-4-[4-(2-hydroxyethoxy)-2-methylbenzoyl]phenyl]amino]phenyl]-3-(2-hydroxyethyl)urea 835624-16-3P, N-[5-Bromo-2-[[3-chloro-4-[2-methyl-4-[2-(tetrahydropyran-2-yloxy)ethoxy]benzoyl]phenyl]amino]phenyl]succinamic acid 835624-17-4P, (4-Allyloxy-2-methylphenyl)[4-(2-amino-4-bromophenylamino)-2-chlorophenyl]methanone 835624-18-5P, N-[2-[(4-Allyloxy-2-methylbenzoyl)-3-chlorophenyl]amino]-5-bromophenylacetamide 835624-19-6P, 1-[2-[(4-Allyloxy-2-methylbenzoyl)-3-chlorophenyl]amino]-5-bromophenyl-3-ethylurea 835624-21-0P, [2-[(4-Allyloxy-2-methylbenzoyl)-3-chlorophenyl]amino]-5-bromophenylcarbamic acid ethyl ester 835624-22-1P, N-[2-[(4-Allyloxy-2-methylbenzoyl)-3-chlorophenyl]amino]-5-bromophenyl]-2,2,2-trifluoroacetamide 835624-23-2P, N-[2-[(4-Allyloxy-2-methylbenzoyl)-3-chlorophenyl]amino]-5-bromophenylsuccinamic acid 835624-24-3P, [2-[(4-Allyloxy-2-methylbenzoyl)-3-chlorophenyl]amino]-5-bromophenylcarbamic acid cyclopentyl ester 835624-25-4P, N-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-methoxypiponamide 835624-26-5P, N-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]propionamide 835624-27-6P, N-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]acetamide 835624-28-7P, N-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-(morpholin-4-yl)propionamide 835624-29-8P, N-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-hydroxypropionamide 835624-30-1P, N-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-(furan-2-yl)propionamide 835624-31-2P, N-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-2-hydroxybenzamide 835624-32-3P, N-[3-[2-Chloro-4-(2,4-

difluorophenylamino)benzoyl]-4-methylphenyl]-2-(2,5-dioxoimidazolidin-4-yl)acetamide 835624-33-4P 835624-34-5P, Acrylic acid  
 2-[3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]carbamoyl[ethyl ester 835624-37-8P,  
 N-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-methylsulfonylpropionamide 835624-38-9P, Ethanesulfonic acid  
 N-[3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]amide 835624-39-0P, N-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-4-methoxybenzenesulfonamide 835624-40-3P,  
 N-[5-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]sulfonyl]-4-methylthiazol-2-ylacetamide 835624-41-4P, 5-Acetyl-2-chloro-N-[3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]benzenesulfonamide 835624-42-5P, Naphthalene-2-sulfonic acid N-[3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]amide 835624-44-7P,  
 N-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-1-phenylmethanesulfonamide 835624-48-1P, 1-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-(2-hydroxyethyl)urea 835624-49-2P, [3-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]ureido]acetic acid ethyl ester 835624-51-6P,  
 1-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-(3-methoxyphenyl)urea 835624-53-8P, 1-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-(3-trifluoromethylphenyl)urea 835624-55-0P, 1-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-propylurea 835624-56-1P, 3-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]ureido]propionic acid ethyl ester 835624-57-2P, 1-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-cyclohexylurea 835624-58-3P, 1-Allyl-3-[3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]urea 835624-59-4P,  
 1-Benzyl-3-[3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]urea 835624-60-7P, 1-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-ethylurea 835624-61-8P, 1-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-phenylurea 835624-62-9P, 1-Butyl-3-[3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]urea 835624-63-0P, 1-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-phenthyleneurea 835624-64-1P, 2-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]ureido]benzoic acid methyl ester 835624-65-2P, 1-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-(3-cyanophenyl)urea 835624-66-3P, 1-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-isopropylurea 835624-67-4P, 1-[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]-3-(4-methoxyphenyl)urea 835624-68-5P, [3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]carbamic acid benzyl ester 835624-69-6P,  
 [3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]carbamic acid allyl ester 835624-70-9P, [3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]carbamic acid ethyl ester 835624-71-0P, [2-Chloro-4-(2,4-difluorophenylamino)phenyl][5-(3-hydroxybutylamino)-2-methylphenyl]methanone 835624-79-8P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2-hydroxyethyl)-4-methylbenzenesulfonamide 835624-80-1P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methyl-N-[2-(morpholin-4-yl)ethyl]benzenesulfonamide 835624-81-2P, N-Allyl-3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzenesulfonamide


835624-82-3P, N-[2-[[3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylphenyl]sulfonyl]amino]ethyl]acetamide  
835624-83-4P  
 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methyl-N-propylbenzenesulfonamide 835624-84-5P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2,3-dihydroxypropyl)-4-methylbenzenesulfonamide 835624-85-6P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2-methoxyethyl)-4-methylbenzenesulfonamide 835624-86-7P, [4-(4-Fluoro-2-methylphenylamino)-2-nitrophenyl]{5-[(4-methoxybenzyl)oxy]-2-methylphenyl}methanone 835624-88-9P, [2-Amino-4-(4-fluoro-2-methylphenylamino)phenyl]{5-(3-hydroxypropoxy)-2-methylphenyl}methanone 835624-91-4P, [2-Amino-4-(4-fluoro-2-methylphenylamino)phenyl]{5-(2,3-dihydroxypropoxy)-2-methylphenyl}methanone 835624-93-6P, [2-Amino-4-(4-fluoro-2-methylphenylamino)phenyl]{2-methyl-5-[2-(morpholin-4-yl)ethoxy]phenyl}methanone 835624-94-7P, [4-(2,4-Difluorophenylamino)-2-nitrophenyl]{5-[(4-methoxybenzyl)oxy]-2-methylphenyl}methanone 835624-96-9P, [2-Amino-4-(2,4-difluorophenylamino)phenyl]{5-(3-hydroxypropoxy)-2-methylphenyl}methanone 835624-97-0P, [4-(2,4-Difluorophenylamino)-2-nitrophenyl]{2-methyl-5-[2-(morpholin-4-yl)ethoxy]phenyl}methanone 835624-98-1P, [2-Amino-4-(2,4-difluorophenylamino)phenyl]{2-methyl-5-[2-(morpholin-4-yl)ethoxy]phenyl}methanone 835625-01-9P, [2-Amino-4-(2,4-difluorophenylamino)phenyl]{5-(2,3-dihydroxypropoxy)-2-methylphenyl}methanone 835625-02-0P, [2-Chloro-4-(2,4-difluorophenylamino)phenyl]{5-(2,3-dihydroxypropoxy)-2-fluorophenyl}methanone 835625-05-3P, 2-[3-[2-Chloro-4-(4-chloro-2-methylphenylamino)benzoyl]-4-fluorophenoxy]-N-methylacetamide 835625-06-4P, [2-Chloro-4-(4-chloro-2-methylphenylamino)phenyl]{2-fluoro-5-(3-hydroxypropoxy)phenyl}methanone 835625-07-5P, 2-[3-[2-Chloro-4-(4-chloro-2-methylphenylamino)benzoyl]-4-fluorophenoxy]-N,N-dimethylacetamide 835625-09-7P, [2-Chloro-4-(4-chloro-2-methylphenylamino)phenyl]{5-(2,3-dihydroxypropoxy)-2-fluorophenyl}methanone 835625-10-0P, [2-Chloro-4-(4-fluoro-2-methylphenylamino)phenyl]{2-fluoro-5-(3-hydroxypropoxy)phenyl}methanone 835625-11-1P, [2-Chloro-4-(4-fluorophenylamino)phenyl]{2-fluoro-5-(3-hydroxypropoxy)phenyl}methanone 835625-13-3P, [2-Chloro-4-(4-fluorophenylamino)phenyl]{5-[2-(2,2-dimethyl-[1,3]dioxolan-4-yl)methoxy]-2-fluorophenyl}methanone 835625-14-4P, [2-Chloro-4-(2-chloro-4-fluorophenylamino)phenyl]{2-fluoro-5-(3-hydroxypropoxy)phenyl}methanone 835625-15-5P, [4-(2-Aminophenylamino)-2-chlorophenyl]{5-(2,3-dihydroxypropoxy)-2-fluorophenyl}methanone 835625-16-6P, [4-(2-Aminophenylamino)-2-chlorophenyl]{5-(2-(morpholin-4-yl)ethoxy)phenyl}methanone 835625-17-7P, [2-Chloro-4-(2,6-difluorophenylamino)phenyl]{2-chloro-5-[2-(morpholin-4-yl)ethoxy]phenyl}methanone 835625-18-8P, [2-Chloro-4-(2,6-difluorophenylamino)phenyl]{2-chloro-5-(2,3-dihydroxypropoxy)phenyl}methanone 835625-19-9P, [5-(3-Bromopropoxy)-2-chlorophenyl]{2-chloro-4-(2,6-difluorophenylamino)phenyl}methanone 835625-23-5P, (5-Aminomethyl-2-methylphenyl){2-chloro-4-(2,4-difluorophenylamino)phenyl}methanone 835625-25-7P, Acetic acid 3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methoxybenzyl ester 835625-26-8P, N-tert-Butoxy-3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methoxybenzamide 835625-27-9P,

3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-methoxy-4-methylbenzamide 835625-28-0P, N-Butoxy-3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzamide 835625-29-1P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-cyclohexylmethoxy-4-methylbenzamide 835625-30-4P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methyl-N-[(2-methylthiazol-4-yl)methoxy]benzamide 835625-32-6P, N-Benzyl oxy-3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzamide 835625-33-7P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-[(4-methoxybenzyl)oxy]-4-methylbenzamide 835625-34-8P, N',N'-Dimethyl-3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzoic hydrazide 835625-35-9P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methyl-N-(morpholin-4-yl)benzamide 835625-36-0P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-hydroxy-4-methylbenzamide 835625-37-1P, 4-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(2-hydroxyethyl)-3-methylbenzamide 835625-39-3P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-[(furan-2-yl)methyl]-4-methylbenzamide 835625-40-6P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-(3-methoxyphenyl)-4-methylbenzamide 835625-42-8P, 3-[3-(2-Chloro-4-(2,4-difluorophenylamino)benzoyl)-4-methylbenzoylamino]thiophene-2-carboxylic acid methyl ester 835625-43-9P, 4-[3-(2-Chloro-4-(2,4-difluorophenylamino)benzoyl)-4-methylbenzoylamino]thiophene-3-carboxylic acid 835625-44-0P, 2-[3-(2-Chloro-4-(2,4-difluorophenylamino)benzoyl)-4-methylbenzoylamino]benzoic acid 835625-45-1P, 3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-N-[2-(2-hydroxyethylcarbamoyl)phenyl]-4-methylbenzamide 835625-46-2P, 3-[3-(2-Chloro-4-(2,4-difluorophenylamino)benzoyl)-4-methylbenzoylamino]thiophene-2-carboxylic acid (2-hydroxyethyl)amide 835625-48-4P, [4-(2-Aminophenylamino)-2-chlorophenyl](5-ethynyl-2-methylphenyl)methanone 835625-52-0P, [2-Chloro-4-(2,4-difluorophenylamino)phenyl](5-ethynyl-2-methylphenyl)methanone 835625-53-1P, 3-[2-Chloro-4-(4-fluorophenylamino)benzoyl]-4-methylbenzoic hydrazide 835625-58-6P 835625-60-0P, 3-[2-Chloro-4-[(2-(3-ethylureido)phenyl)amino]benzoyl]-N-(2-hydroxyethyl)-4-methylbenzamide 835625-62-2P, [2-Chloro-4-(2,4-difluorophenylamino)phenyl][5-(3-hydroxyprop-1-enyl)-2-methylphenyl]methanone 835625-63-3P, 3-[2-Chloro-4-(2-nitrophenylamino)benzoyl]-N-(2-hydroxyethyl)-4-methylbenzamide 835625-64-4P, 3-[4-(4-Bromo-2-nitrophenylamino)-2-chlorobenzoyl]-N-(2-hydroxyethyl)-4-methylbenzamide 835625-65-5P, 3-[2-Chloro-4-(2-nitrophenylamino)benzoyl]-N-(2-methoxyethyl)-4-methylbenzamide 835625-66-6P, 3-[2-Chloro-4-(4-fluorophenylamino)benzoyl]-4-methoxybenzoic acid 835625-67-7P, 3-(2-Chloro-4-phenylaminobenzoyl)-4-methoxybenzoic acid 835625-68-8P, [2-Chloro-4-(2-nitrophenylamino)phenyl][2-methyl-4-[2-[(tetrahydropyran-2-yl)oxy]ethoxy]phenyl]methanone  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (p38 $\alpha$  MAP kinase inhibitor; preparation of aminobenzophenones as inhibitors of IL-1 $\beta$  and TNF- $\alpha$  production for treating inflammatory diseases or conditions)


RN 835622-75-8 CAPLUS  
 CN Morpholine, 4-[3-[2-chloro-4-[(4-fluoro-2-methylphenyl)amino]benzoyl]-4-methylbenzoyl]- (9CI) (CA INDEX NAME)




RN 835622-76-9 CAPLUS  
CN Piperazine, 1-[3-[2-chloro-4-[(4-fluoro-2-methylphenyl)amino]benzoyl]-4-methylbenzoyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 835622-77-0 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(4-fluoro-2-methylphenyl)amino]benzoyl]-N-methoxy-N,4-dimethyl- (CA INDEX NAME)




RN 835622-78-1 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(4-fluoro-2-methylphenyl)amino]benzoyl]-4-methyl-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)




RN 835622-79-2 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(4-fluoro-2-methylphenyl)amino]benzoyl]-N,4-dimethyl-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)




RN 835622-80-5 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(4-fluoro-2-methylphenyl)amino]benzoyl]-N-(2-methoxyethyl)-4-methyl- (CA INDEX NAME)




RN 835622-81-6 CAPLUS


CN Benzamide, 3-[2-chloro-4-[(4-fluoro-2-methylphenyl)amino]benzoyl]-4-methyl-N-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)




RN 835622-82-7 CAPLUS  
CN Piperazine, 1-[3-[2-chloro-4-[(4-fluoro-2-methylphenyl)amino]benzoyl]-4-methylbenzoyl]-4-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 835622-83-8 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(4-fluoro-2-methylphenyl)amino]benzoyl]-4-methyl-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 835622-84-9 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(4-fluoro-2-methylphenyl)amino]benzoyl]-4-methyl-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 835622-85-0 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(4-fluoro-2-methylphenyl)amino]benzoyl]-4-methyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 835622-87-2 CAPLUS  
CN Benzamide, 3-[4-[(2-amino-4-bromophenyl)amino]-2-chlorobenzoyl]-N-(2-hydroxyethyl)-4-methyl- (CA INDEX NAME)




RN 835622-88-3 CAPLUS  
CN Benzoic acid, 3-[4-[(4-bromo-2-methylphenyl)amino]-2-chlorobenzoyl]-4-methyl- (CA INDEX NAME)




RN 835622-89-4 CAPLUS  
CN Benzamide, 3-[4-[(4-bromo-2-methylphenyl)amino]-2-chlorobenzoyl]-N-(2-hydroxyethyl)-4-methyl- (CA INDEX NAME)




RN 835622-91-8 CAPLUS  
CN 2-Propenoic acid, 2-methyl-, 2-[[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylbenzoyl]amino]ethyl ester (CA INDEX NAME)




RN 835622-93-0 CAPLUS  
CN Benzamide, 3-[4-[(2-aminophenyl)amino]-2-chlorobenzoyl]-N-(2-methoxyethyl)-4-methyl- (CA INDEX NAME)




RN 835622-95-2 CAPLUS  
CN Benzamide, 3-[4-[(2-aminophenyl)amino]-2-chlorobenzoyl]-N-ethyl-4-methyl-  
(CA INDEX NAME)




RN 835622-96-3 CAPLUS  
CN Benzamide, 3-[4-[(2-aminophenyl)amino]-2-chlorobenzoyl]-N-(3-hydroxypropyl)-4-methyl- (CA INDEX NAME)




RN 835622-97-4 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(4-fluoro-2-methylphenyl)amino]benzoyl]-N-(2-hydroxyethyl)-4-methyl- (CA INDEX NAME)




RN 835622-99-6 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(4-chloro-2-fluorophenyl)amino]benzoyl]-N-(2-hydroxyethyl)-4-methyl- (CA INDEX NAME)




RN 835623-00-2 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(4-chloro-2-fluorophenyl)amino]benzoyl]-N,4-dimethyl- (CA INDEX NAME)




RN 835623-02-4 CAPLUS  
CN Glycine, N-[3-[2-chloro-4-[(4-chloro-2-fluorophenyl)amino]benzoyl]-4-methylbenzoyl]-, ethyl ester (CA INDEX NAME)




RN 835623-03-5 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(4-chloro-2-fluorophenyl)amino]benzoyl]-N-(2-methoxyethyl)-4-methyl- (CA INDEX NAME)




RN 835623-04-6 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(4-chloro-2-fluorophenyl)amino]benzoyl]-N-cyclohexyl-4-methyl- (CA INDEX NAME)




RN 835623-05-7 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(4-chloro-2-fluorophenyl)amino]benzoyl]-N-ethyl-4-methyl- (CA INDEX NAME)




RN 835623-06-8 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(4-chloro-2-fluorophenyl)amino]benzoyl]-N-(6-hydroxyhexyl)-4-methyl- (CA INDEX NAME)




RN 835623-07-9 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(4-chloro-2-fluorophenyl)amino]benzoyl]-4-methyl-N-(1-methylethyl)- (CA INDEX NAME)




RN 835623-08-0 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(4-chloro-2-fluorophenyl)amino]benzoyl]-4-methyl-N-(2-methylpropyl)- (CA INDEX NAME)




RN 835623-09-1 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(4-chloro-2-fluorophenyl)amino]benzoyl]-N-(2,2-dimethylpropyl)-4-methyl- (CA INDEX NAME)



RN 835623-10-4 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(4-chloro-2-fluorophenyl)amino]benzoyl]-N-(3-methoxypropyl)-4-methyl- (CA INDEX NAME)




RN 835623-11-5 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(4-chloro-2-fluorophenyl)amino]benzoyl]-4-methyl-N-(3-(2-oxo-1-pyrrolidinyl)propyl)- (CA INDEX NAME)



RN 835623-12-6 CAPLUS


CN Benzamide, 3-[2-chloro-4-[(4-chloro-2-fluorophenyl)amino]benzoyl]-N-[2-(dimethylamino)ethyl]-4-methyl- (CA INDEX NAME)



RN 835623-14-8 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(4-chloro-2-fluorophenyl)amino]benzoyl]-N-(cis-4-hydroxycyclohexyl)-4-methyl- (CA INDEX NAME)

Relative stereochemistry.




RN 835623-15-9 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(4-chloro-2-fluorophenyl)amino]benzoyl]-N-(trans-


4-hydroxycyclohexyl)-4-methyl- (CA INDEX NAME)

Relative stereochemistry.




RN 835623-17-1 CAPLUS

CN Benzamide, N-(2-aminoethyl)-3-[2-chloro-4-[(4-chloro-2-fluorophenyl)amino]benzoyl]-4-methyl- (CA INDEX NAME)




RN 835623-18-2 CAPLUS

CN Glycine, N-[3-[2-chloro-4-[(4-chloro-2-fluorophenyl)amino]benzoyl]-4-methylbenzoyl]glycyl- (CA INDEX NAME)




RN 835623-20-6 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2-hydroxyethyl)-4-methoxy- (CA INDEX NAME)




RN 835623-21-7 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2,2-difluoroethyl)-4-methoxy- (CA INDEX NAME)




RN 835623-22-8 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2-fluoroethyl)-4-methoxy- (CA INDEX NAME)




RN 835623-23-9 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2,3-dihydroxypropyl)-4-methoxy- (CA INDEX NAME)




RN 835623-24-0 CAPLUS

CN Benzamide, N-(2-amino-2-oxoethyl)-3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methoxy- (CA INDEX NAME)




RN 835623-25-1 CAPLUS

CN Benzamide, N-(2-amino-2-oxoethyl)-3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl- (CA INDEX NAME)




RN 835623-26-2 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 835623-27-3 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2-fluoroethyl)-4-methyl- (CA INDEX NAME)




RN 835623-28-4 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 835623-29-5 CAPLUS


CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-ethyl-4-methyl- (CA INDEX NAME)




RN 835623-30-8 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(cyclohexylmethyl)-4-methyl- (CA INDEX NAME)



RN 835623-31-9 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2-hydroxypropyl)-4-methyl- (CA INDEX NAME)




RN 835623-32-0 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2,3-dihydroxypropyl)-4-methyl- (CA INDEX NAME)




RN 835623-33-1 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-[1-(hydroxymethyl)propyl]-4-methyl- (CA INDEX NAME)




RN 835623-34-2 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-N-(2,2,3,3,3-pentafluoropropyl)- (CA INDEX NAME)




RN 835623-35-3 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(3-hydroxypropyl)-4-methyl- (CA INDEX NAME)




RN 835623-36-4 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2-hydroxy-1,1-dimethylethyl)-4-methyl- (CA INDEX NAME)




RN 835623-37-5 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2-hydroxy-1-(hydroxymethyl)-1-methylethyl)-4-methyl- (CA INDEX NAME)




RN 835623-38-6 CAPLUS

CN Glycine, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylbenzoyl]-, ethyl ester (CA INDEX NAME)




RN 835623-39-7 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(4-hydroxybutyl)-4-methyl- (CA INDEX NAME)




RN 835623-40-0 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(3-hydroxy-1,1-dimethylbutyl)-4-methyl- (CA INDEX NAME)



RN 835623-41-1 CAPLUS


CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-N-(3-phenylpropyl)- (CA INDEX NAME)



RN 835623-42-2 CAPLUS


CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-[(1R)-1-(hydroxymethyl)-3-methylbutyl]-4-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 835623-44-4 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-N-(1-methylethyl)- (CA INDEX NAME)




RN 835623-45-5 CAPLUS


CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-cyclohexyl-4-methyl- (CA INDEX NAME)




RN 835623-46-6 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2,2-difluoroethyl)-4-methyl- (CA INDEX NAME)



RN 835623-47-7 CAPLUS  
CN Pentanoic acid, 5-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylbenzoyl]amino]-4-oxo-, methyl ester (CA INDEX NAME)




RN 835623-48-8 CAPLUS  
CN  $\beta$ -Alaninamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylbenzoyl]glycyl- (9CI) (CA INDEX NAME)




BN 835623-49-9 CAPLUS

CN Glycine, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylbenzoyl]glycyl-, ethyl ester (CA INDEX NAME)




RN 835623-50-2 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-N-2-propen-1-yl- (CA INDEX NAME)




BN 835623-51-3 CAPLUS

CN Benzamide, N-[2-(aminosulfonyl)ethyl]-3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl- (CA INDEX NAME)




RN 835623-52-4 CAPLUS

CN Benzamide, N-[2-(ethylamino)ethyl]-3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl- (CA INDEX NAME)




RN 835623-53-5 CAPLUS

CN Benzoic acid, 3-[2-chloro-4-[(2,6-difluorophenyl)amino]benzoyl]-4-methoxy- (CA INDEX NAME)




RN 835623-54-6 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,6-difluorophenyl)amino]benzoyl]-N-(2-hydroxyethyl)-4-methoxy- (CA INDEX NAME)




RN 835623-55-7 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,6-difluorophenyl)amino]benzoyl]-N-(2-fluoroethyl)-4-methoxy- (CA INDEX NAME)




RN 835623-56-8 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,6-difluorophenyl)amino]benzoyl]-N-(2,3-dihydroxypropyl)-4-methoxy- (CA INDEX NAME)




RN 835623-57-9 CAPLUS


CN Benzamide, 3-[2-chloro-4-[(2,6-difluorophenyl)amino]benzoyl]-N-(3-hydroxypropyl)-4-methoxy- (CA INDEX NAME)




RN 835623-58-0 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(2,6-difluorophenyl)amino]benzoyl]-4-methoxy-N-(2-phenylethyl)- (CA INDEX NAME)




RN 835623-59-1 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(2,6-difluorophenyl)amino]benzoyl]-N-(2-hydroxy-1,1-dimethylethyl)-4-methoxy- (CA INDEX NAME)




RN 835623-60-4 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(2,6-difluorophenyl)amino]benzoyl]-4-methoxy-N-(2-(4-morpholinyl)ethyl)- (CA INDEX NAME)




RN 835623-61-5 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(2,6-difluorophenyl)amino]benzoyl]-N-[2-hydroxymethyl-1-(hydroxymethyl)-1-methylethyl]-4-methoxy- (CA INDEX NAME)



RN 835623-62-6 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(2,6-difluorophenyl)amino]benzoyl]-N-(2-hydroxyethyl)-4-methoxy-N-methyl- (CA INDEX NAME)




RN 835623-63-7 CAPLUS  
CN Glycine, N-[3-[2-chloro-4-[(2,6-difluorophenyl)amino]benzoyl]-4-methoxybenzoyl]-, ethyl ester (CA INDEX NAME)




RN 835623-64-8 CAPLUS

CN Glycine, N-[3-[2-chloro-4-[(2,6-difluorophenyl)amino]benzoyl]-4-methoxybenzoyl]glycyl-, ethyl ester (CA INDEX NAME)




RN 835623-65-9 CAPLUS

CN Benzanide, 3-[2-chloro-4-[(2,6-difluorophenyl)amino]benzoyl]-N,N-bis(2-hydroxyethyl)-4-methoxy- (CA INDEX NAME)




RN 835623-66-0 CAPLUS


CN Benzanide, 3-[2-chloro-4-[(2,6-difluorophenyl)amino]benzoyl]-4-methoxy-N,N-bis(2-methoxyethyl)- (CA INDEX NAME)




RN 835623-67-1 CAPLUS  
CN Benzoic acid, 3-[2-chloro-4-[(3-fluoro-2-methylphenyl)amino]benzoyl]-4-methyl- (CA INDEX NAME)




RN 835623-68-2 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(3-fluoro-2-methylphenyl)amino]benzoyl]-N-(2-hydroxyethyl)-4-methyl- (CA INDEX NAME)




RN 835623-69-3 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(3-fluoro-2-methylphenyl)amino]benzoyl]-4-methyl-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 835623-70-6 CAPLUS  
CN Benzoic acid, 3-[2-chloro-4-[(2-chloro-4-fluorophenyl)amino]benzoyl]-4-methyl- (CA INDEX NAME)




RN 835623-71-7 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(2-chloro-4-fluorophenyl)amino]benzoyl]-N-(2-hydroxyethyl)-4-methyl- (CA INDEX NAME)




RN 835623-72-8 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(2-chloro-4-fluorophenyl)amino]benzoyl]-4-methyl-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 835623-73-9 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(4-fluorophenyl)amino]benzoyl]-N-(2-hydroxyethyl)-4-methyl- (CA INDEX NAME)




RN 835623-74-0 CAPLUS  
CN Benzamide, 3-[2-chloro-4-(phenylamino)benzoyl]-N-(2-hydroxyethyl)-4-methyl- (CA INDEX NAME)




RN 835623-75-1 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(3,5-difluorophenyl)amino]benzoyl]-N-(2-hydroxyethyl)-4-methyl- (CA INDEX NAME)




RN 835623-76-2 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(3-fluorophenyl)amino]benzoyl]-N-(2-hydroxyethyl)-4-methyl- (CA INDEX NAME)




RN 835623-77-3 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(4-fluorophenyl)amino]benzoyl]-N-(2-hydroxyethyl)-4-methoxy- (CA INDEX NAME)




RN 835623-78-4 CAPLUS  
CN Benzamide, 3-[2-chloro-4-(phenylamino)benzoyl]-N-(2-hydroxyethyl)-4-methoxy- (CA INDEX NAME)




RN 835623-79-5 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(4-fluorophenyl)amino]benzoyl]-N-(2,2-difluoroethyl)-4-methoxy- (CA INDEX NAME)



RN 835623-80-8 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(4-fluorophenyl)amino]benzoyl]-N-(2-fluoroethyl)-4-methoxy- (CA INDEX NAME)




RN 835623-81-9 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(4-fluorophenyl)amino]benzoyl]-N-(2,3-dihydroxypropyl)-4-methoxy- (CA INDEX NAME)




RN 835623-82-0 CAPLUS

CN Benzamide, N-(2-amino-2-oxoethyl)-3-[2-chloro-4-[(4-fluorophenyl)amino]benzoyl]-4-methoxy- (CA INDEX NAME)




RN 835623-83-1 CAPLUS

CN Benzamide, 3-[2-chloro-4-(phenylamino)benzoyl]-N-(2,2-difluoroethyl)-4-methoxy- (CA INDEX NAME)




RN 835623-84-2 CAPLUS


CN Benzamide, 3-[2-chloro-4-(phenylamino)benzoyl]-N-(2-fluoroethyl)-4-methoxy- (CA INDEX NAME)




RN 835623-85-3 CAPLUS  
CN Benzamide, 3-[2-chloro-4-(phenylamino)benzoyl]-N-(2,3-dihydroxypropyl)-4-methoxy- (CA INDEX NAME)



RN 835623-86-4 CAPLUS  
CN Benzamide, N-(2-amino-2-oxoethyl)-3-[2-chloro-4-(phenylamino)benzoyl]-4-methoxy- (CA INDEX NAME)




RN 835623-87-5 CAPLUS  
CN Benzamide, 4-chloro-3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 835623-88-6 CAPLUS

CN Carbamic acid, [2-[3-chloro-4-[[2-hydroxyethyl]amino]carbonyl]-2-methylbenzoylphenyl]amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 835623-89-7 CAPLUS

CN Benzamide, 3-[2-chloro-4-[[2-[(1-oxopropyl)aminophenyl]amino]benzoyl]-N-(2-hydroxyethyl)-4-methyl- (CA INDEX NAME)




RN 835623-90-0 CAPLUS


CN Benzamide, 3-[4-[[2-(acetylamino)phenyl]amino]-2-chlorobenzoyl]-N-(2-hydroxyethyl)-4-methyl- (CA INDEX NAME)




RN 835623-91-1 CAPLUS  
CN Butanoic acid, 4-[2-[[3-chloro-4-[(2-hydroxyethyl)amino]carbonyl]-2-methylbenzoyl]phenyl]amino]-4-oxo- (CA INDEX NAME)



RN 835623-92-2 CAPLUS  
CN Benzanide, 3-[2-chloro-4-[(2-[(2-hydroxyethyl)amino]carbonyl)amino]phenyl]amino]benzoyl-N-(2-hydroxyethyl)-4-methyl- (CA INDEX NAME)




RN 835623-93-3 CAPLUS  
CN Morpholine, 4-[4-(2-chloro-4-[(4-fluoro-2-methylphenyl)amino]benzoyl)-3-methylbenzoyl]- (9CI) (CA INDEX NAME)




RN 835623-97-7 CAPLUS

CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl][4-(2-hydroxyethoxy)-2-methylphenyl]- (CA INDEX NAME)




RN 835623-98-8 CAPLUS

CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl][2-methyl-4-[3-[(tetrahydro-2H-pyran-2-yl)oxyl]propoxy]phenyl]- (CA INDEX NAME)




RN 835623-99-9 CAPLUS

CN Methanone, [4-[{(2-amino-4-bromophenyl)amino]-2-chlorophenyl}[4-(3-hydroxypropoxy)-2-methylphenyl]- (CA INDEX NAME)




RN 835624-00-5 CAPLUS

CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl][4-(2-fluoroethoxy)-2-methylphenyl]- (CA INDEX NAME)




RN 835624-01-6 CAPLUS

CN Methanone, [4-[(2-bromo-4-methylphenyl)amino]-2-chlorophenyl][4-(2-fluoroethoxy)-2-methylphenyl]- (CA INDEX NAME)




RN 835624-02-7 CAPLUS

CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl][4-(2-methoxyethoxy)-2-methylphenyl]- (CA INDEX NAME)




RN 835624-06-1 CAPLUS

CN Methanone, [4-(2-aminoethoxy)-2-methylphenyl][4-[(4-bromo-2-methylphenyl)amino]-2-chlorophenyl]- (CA INDEX NAME)




RN 835624-09-4 CAPLUS

CN Methanone, [4-[(2-(3-amino-1-propen-1-yl)phenyl)amino]-2-chlorophenyl][4-(2-hydroxyethoxy)-2-methylphenyl]- (CA INDEX NAME)




RN 835624-10-7 CAPLUS

CN Urea, N-[2-[(3-chloro-4-[4-(2-hydroxyethoxy)-2-methylbenzoyl]phenyl)aminophenyl]-N'-ethyl- (CA INDEX NAME)




RN 835624-12-9 CAPLUS


CN Urea, N-[5-bromo-2-[(3-chloro-4-[4-(2-hydroxyethoxy)-2-methylbenzoyl]phenyl)aminophenyl]-N'-ethyl- (CA INDEX NAME)




RN 835624-13-0 CAPLUS  
CN Urea, N-[5-bromo-2-[(3-chloro-4-[2-methyl-4-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]benzoyl)phenyl]amino]phenyl-N'-cyclohexyl- (CA INDEX NAME)




RN 835624-15-2 CAPLUS  
CN Urea, N-[5-bromo-2-[(3-chloro-4-[(2-hydroxyethoxy)-2-methylbenzoyl]phenyl)amino]phenyl]-N'-(2-hydroxyethyl)- (CA INDEX NAME)




RN 835624-16-3 CAPLUS  
CN Butanoic acid, 4-[(5-bromo-2-[(3-chloro-4-[2-methyl-4-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]benzoyl)phenyl]amino)-4-oxo- (CA INDEX NAME)




RN 835624-17-4 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl][2-methyl-4-(2-propen-1-yloxy)phenyl]- (CA INDEX NAME)



RN 835624-18-5 CAPLUS  
CN Acetamide, N-[5-bromo-2-[(3-chloro-4-[2-methyl-4-(2-propen-1-yloxy)benzoyl]phenyl]amino]phenyl]- (CA INDEX NAME)




RN 835624-19-6 CAPLUS  
CN Urea, N-[5-bromo-2-[(3-chloro-4-[2-methyl-4-(2-propen-1-yloxy)benzoyl]phenyl]amino]phenyl]-N'-ethyl- (CA INDEX NAME)




RN 835624-21-0 CAPLUS

CN Carbanic acid, [5-bromo-2-[(3-chloro-4-[2-methyl-4-(2-propenoxy)benzoyl]phenyl]amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 835624-22-1 CAPLUS

CN Acetanide, N-[5-bromo-2-[(3-chloro-4-[2-methyl-4-(2-propenoxy)benzoyl]phenyl]amino]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 835624-23-2 CAPLUS

CN Butanoic acid, 4-[(5-bromo-2-[(3-chloro-4-[2-methyl-4-(2-propenoxy)benzoyl]phenyl]amino)phenyl]amino]-4-oxo- (CA INDEX NAME)




RN 835624-24-3 CAPLUS

CN Carbanic acid, [5-bromo-2-[(3-chloro-4-[2-methyl-4-(2-propenoxy)benzoyl]phenyl]amino]phenyl]-, cyclopentyl ester (9CI) (CA INDEX NAME)




RN 835624-25-4 CAPLUS

CN Propanamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-3-methoxy- (CA INDEX NAME)




RN 835624-26-5 CAPLUS

CN Propanamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]- (CA INDEX NAME)




RN 835624-27-6 CAPLUS

CN Acetamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-2-(2-methoxyethoxy)- (CA INDEX NAME)




RN 835624-28-7 CAPLUS

CN 4-Morpholinepropanamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]- (CA INDEX NAME)




RN 835624-29-8 CAPLUS


CN Propanamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-3-hydroxy- (CA INDEX NAME)




RN 835624-30-1 CAPLUS  
CN 2-Furanpropanamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]- (CA INDEX NAME)



RN 835624-31-2 CAPLUS  
CN Benzamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-2-hydroxy- (CA INDEX NAME)




RN 835624-32-3 CAPLUS  
CN 4-Imidazolidineacetamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-2,5-dioxo- (CA INDEX NAME)




RN 835624-33-4 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]hexahydro-2,6-dioxo- (CA INDEX NAME)




RN 835624-34-5 CAPLUS

CN 2-Propenoic acid, 3-[[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]amino]-3-oxopropyl ester (CA INDEX NAME)




RN 835624-37-8 CAPLUS


CN Propanamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-3-(methylsulfonyl)- (CA INDEX NAME)




RN 835624-38-9 CAPLUS  
CN Ethanesulfonamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]- (CA INDEX NAME)




RN 835624-39-0 CAPLUS  
CN Benzenesulfonamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-4-methoxy- (CA INDEX NAME)




RN 835624-40-3 CAPLUS  
CN Acetamide, N-[5-[[3-(2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl)-4-methylphenyl]amino]sulfonyl]-4-methyl-2-thiazolyl]- (CA INDEX NAME)




RN 835624-41-4 CAPLUS  
CN Benzenesulfonamide, 5-acetyl-2-chloro-N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]- (CA INDEX NAME)




RN 835624-42-5 CAPLUS  
CN 2-Naphthalenesulfonamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]- (CA INDEX NAME)




RN 835624-44-7 CAPLUS  
CN Benzenemethanesulfonamide, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]- (CA INDEX NAME)




RN 835624-48-1 CAPLUS  
CN Urea, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N'-(2-hydroxyethyl)- (CA INDEX NAME)




RN 835624-49-2 CAPLUS  
CN Glycine, N-[{(3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 835624-51-6 CAPLUS  
CN Urea, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N'-(3-methoxyphenyl)- (CA INDEX NAME)




RN 835624-53-8 CAPLUS  
CN Urea, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 835624-55-0 CAPLUS  
CN Urea, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N'-propyl- (CA INDEX NAME)




RN 835624-56-1 CAPLUS  
CN  $\beta$ -Alanine, N-[[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 835624-57-2 CAPLUS  
CN Urea, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N'-cyclohexyl- (CA INDEX NAME)




RN 835624-58-3 CAPLUS  
CN Urea, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N'-2-propen-1-yl- (CA INDEX NAME)




RN 835624-59-4 CAPLUS  
CN Urea, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N'-(phenylmethyl)- (CA INDEX NAME)




RN 835624-60-7 CAPLUS  
CN Urea, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N'-ethyl- (CA INDEX NAME)




RN 835624-61-8 CAPLUS  
CN Urea, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N'-phenyl- (CA INDEX NAME)




RN 835624-62-9 CAPLUS  
CN Urea, N-butyl-N'-(3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl)- (CA INDEX NAME)




RN 835624-63-0 CAPLUS  
CN Urea, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N'-(2-phenylethyl)- (CA INDEX NAME)



RN 835624-64-1 CAPLUS  
CN Benzoic acid, 2-[[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]amino]carbonyl]-, methyl ester (CA INDEX NAME)




RN 835624-65-2 CAPLUS  
CN Urea, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N'-(3-cyanophenyl)- (CA INDEX NAME)




RN 835624-66-3 CAPLUS

CN Urea, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N'-(1-methylethyl)- (CA INDEX NAME)




RN 835624-67-4 CAPLUS

CN Urea, N-[3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-N'-(4-methoxyphenyl)- (CA INDEX NAME)




RN 835624-68-5 CAPLUS

CN Carbamic acid, [3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 835624-69-6 CAPLUS

CN Carbamic acid, [3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 835624-70-9 CAPLUS

CN Carbamic acid, [3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 835624-71-0 CAPLUS


CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-[(3-hydroxybutyl)amino]-2-methylphenyl]- (CA INDEX NAME)




RN 835624-79-8 CAPLUS  
CN Benzenesulfonamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2-hydroxyethyl)-4-methyl- (CA INDEX NAME)




RN 835624-80-1 CAPLUS  
CN Benzenesulfonamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 835624-81-2 CAPLUS  
CN Benzenesulfonamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-N-2-propen-1-yl- (CA INDEX NAME)




RN 835624-82-3 CAPLUS  
CN Acetamide, N-[2-[(3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylphenyl)sulfonyl]amino]ethyl- (CA INDEX NAME)




RN 835624-83-4 CAPLUS  
CN Benzenesulfonamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-N-propyl- (CA INDEX NAME)




RN 835624-84-5 CAPLUS  
CN Benzenesulfonamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2,3-dihydroxypropyl)-4-methyl- (CA INDEX NAME)




RN 835624-85-6 CAPLUS  
CN Benzenesulfonamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2-methoxyethyl)-4-methyl- (CA INDEX NAME)




RN 835624-86-7 CAPLUS  
CN Methanone, [4-[(4-fluoro-2-methylphenyl)amino]-2-nitrophenyl][5-[(4-methoxyphenyl)methoxy]-2-methylphenyl]- (CA INDEX NAME)




RN 835624-88-9 CAPLUS  
CN Methanone, [2-amino-4-[(4-fluoro-2-methylphenyl)amino]phenyl][5-(3-hydroxypropoxy)-2-methylphenyl]- (CA INDEX NAME)




RN 835624-91-4 CAPLUS  
CN Methanone, [2-amino-4-[(4-fluoro-2-methylphenyl)amino]phenyl][5-(2,3-dihydroxypropoxy)-2-methylphenyl]- (CA INDEX NAME)




RN 835624-93-6 CAPLUS  
CN Methanone, [2-amino-4-[(4-fluoro-2-methylphenyl)amino]phenyl][2-methyl-5-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)




RN 835624-94-7 CAPLUS  
CN Methanone, [4-[(2,4-difluorophenyl)amino]-2-nitrophenyl][5-[(4-methoxyphenyl)methoxy]-2-methylphenyl]- (CA INDEX NAME)




RN 835624-96-9 CAPLUS  
CN Methanone, [2-amino-4-[(2,4-difluorophenyl)amino]phenyl][5-(3-hydroxypropoxy)-2-methylphenyl]- (CA INDEX NAME)




RN 835624-97-0 CAPLUS  
CN Methanone, [4-[(2,4-difluorophenyl)amino]-2-nitrophenyl][2-methyl-5-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)




RN 835624-98-1 CAPLUS  
CN Methanone, [2-amino-4-[(2,4-difluorophenyl)amino]phenyl][2-methyl-5-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)




RN 835625-01-9 CAPLUS  
CN Methanone, [2-amino-4-[(2,4-difluorophenyl)amino]phenyl][5-(2,3-dihydroxypropoxy)-2-methylphenyl]- (CA INDEX NAME)




RN 835625-02-0 CAPLUS  
CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][2-fluoro-5-(3-hydroxypropoxy)phenyl]- (CA INDEX NAME)




RN 835625-04-2 CAPLUS  
CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-(2,3-dihydroxypropoxy)-2-fluorophenyl]- (CA INDEX NAME)




RN 835625-05-3 CAPLUS  
CN Acetamide, 2-[3-[2-chloro-4-[(4-chloro-2-methylphenyl)amino]benzoyl]-4-fluorophenoxy]-N-methyl- (CA INDEX NAME)




RN 835625-06-4 CAPLUS  
CN Methanone, [2-chloro-4-[(4-chloro-2-methylphenyl)amino]phenyl][2-fluoro-5-(3-hydroxypropoxy)phenyl]- (CA INDEX NAME)




RN 835625-07-5 CAPLUS  
CN Acetamide, 2-[3-[2-chloro-4-[(4-chloro-2-methylphenyl)amino]benzoyl]-4-fluorophenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 835625-09-7 CAPLUS  
CN Methanone, [2-chloro-4-[(4-chloro-2-methylphenyl)amino]phenyl][5-(2,3-dihydroxypropoxy)-2-fluorophenyl]- (CA INDEX NAME)




RN 835625-10-0 CAPLUS  
CN Methanone, [2-chloro-4-[(4-fluoro-2-methylphenyl)amino]phenyl][2-fluoro-5-(3-hydroxypropoxy)phenyl]- (CA INDEX NAME)




RN 835625-11-1 CAPLUS  
CN Methanone, [2-chloro-4-[(4-fluorophenyl)amino]phenyl][2-fluoro-5-(3-hydroxypropoxy)phenyl]- (CA INDEX NAME)




RN 835625-13-3 CAPLUS  
CN Methanone, [2-chloro-4-[(4-fluorophenyl)amino]phenyl][5-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-2-fluorophenyl]- (CA INDEX NAME)




RN 835625-14-4 CAPLUS  
CN Methanone, [2-chloro-4-[(2-chloro-4-fluorophenyl)amino]phenyl][2-fluoro-5-(3-hydroxypropoxy)phenyl]- (CA INDEX NAME)




RN 835625-15-5 CAPLUS  
CN Methanone, [4-[(2-aminophenyl)amino]-2-chlorophenyl][5-(2,3-dihydroxypropoxy)-2-fluorophenyl]- (CA INDEX NAME)




RN 835625-16-6 CAPLUS  
CN Methanone, [4-[(2-aminophenyl)amino]-2-chlorophenyl][2-fluoro-5-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 835625-17-7 CAPLUS  
CN Methanone, [2-chloro-4-[(2,6-difluorophenyl)amino]phenyl][2-chloro-5-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)




RN 835625-18-8 CAPLUS  
CN Methanone, [2-chloro-4-[(2,6-difluorophenyl)amino]phenyl][2-chloro-5-(2,3-dihydroxypropoxy)phenyl]- (CA INDEX NAME)




RN 835625-19-9 CAPLUS

CN Methanone, [5-(3-bromopropoxy)-2-chlorophenyl][2-chloro-4-[(2,6-difluorophenyl)aminophenyl]- (CA INDEX NAME)




RN 835625-23-5 CAPLUS

CN Methanone, [5-(aminomethyl)-2-methylphenyl][2-chloro-4-[(2,4-difluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 835625-25-7 CAPLUS


CN Methanone, [5-[(acetyloxy)methyl]-2-methoxyphenyl][2-chloro-4-[(2,4-difluorophenyl)amino]phenyl]- (CA INDEX NAME)




RN 835625-26-8 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(1,1-dimethylethoxy)-4-methoxy- (CA INDEX NAME)




RN 835625-27-9 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-methoxy-4-methyl- (CA INDEX NAME)




RN 835625-28-0 CAPLUS  
CN Benzamide, N-butoxy-3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl- (CA INDEX NAME)




RN 835625-29-1 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(cyclohexylmethoxy)-4-methyl- (CA INDEX NAME)



RN 835625-30-4 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-N-[(2-methyl-4-thiazolyl)methoxy]- (CA INDEX NAME)




RN 835625-32-6 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-N-(phenylmethoxy)- (CA INDEX NAME)




RN 835625-33-7 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-[(4-methoxyphenyl)methoxymethyl]-4-methyl- (CA INDEX NAME)




RN 835625-34-8 CAPLUS

CN Benzoic acid, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-2,2-dimethylhydrazide (CA INDEX NAME)




RN 835625-35-9 CAPLUS


CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-N-4-morpholinyl- (CA INDEX NAME)




RN 835625-36-0 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-hydroxy-4-methyl- (CA INDEX NAME)



RN 835625-37-1 CAPLUS  
CN Benzamide, 4-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2-hydroxyethyl)-3-methyl- (CA INDEX NAME)




RN 835625-39-3 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(2-furylmethyl)-4-methyl- (CA INDEX NAME)




RN 835625-40-6 CAPLUS

CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-(3-methoxyphenyl)-4-methyl- (CA INDEX NAME)




RN 835625-42-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylbenzoyl)amino]-, methyl ester (CA INDEX NAME)




RN 835625-43-9 CAPLUS


CN 3-Thiophenecarboxylic acid, 4-[(3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylbenzoyl)amino]- (CA INDEX NAME)



RN 835625-44-0 CAPLUS  
CN Benzoic acid, 2-[(3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methylbenzoyl]amino]- (CA INDEX NAME)




RN 835625-45-1 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-N-[2-[(2-hydroxyethyl)amino]carbonyl]phenyl]-4-methyl- (CA INDEX NAME)




RN 835625-46-2 CAPLUS  
CN 2-Thiophene carboxamide, 3-[(3-[2-chloro-4-[(2,4-

difluorophenyl)amino]benzoyl]-4-methylbenzoyl]amino]-N-(2-hydroxyethyl)-  
(CA INDEX NAME)




RN 835625-48-4 CAPLUS

CN Methanone, [4-[(2-aminophenyl)amino]-2-chlorophenyl](5-ethynyl-2-methylphenyl)- (CA INDEX NAME)




RN 835625-52-0 CAPLUS

CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl](5-ethynyl-2-methylphenyl)- (CA INDEX NAME)




RN 835625-53-1 CAPLUS


CN Benzoic acid, 3-[2-chloro-4-[(4-fluorophenyl)amino]benzoyl]-4-methyl-, hydrazide (CA INDEX NAME)




RN 835625-58-6 CAPLUS  
CN Benzenepropanoic acid, 3-[2-chloro-4-[(2,4-difluorophenyl)amino]benzoyl]-4-methyl-β-oxo-, ethyl ester (CA INDEX NAME)




RN 835625-60-0 CAPLUS  
CN Benzanide, 3-[2-chloro-4-[(2-[(ethylamino)carbonyl]amino)phenyl]amino]benzoyl]-N-(2-hydroxyethyl)-4-methyl- (CA INDEX NAME)




RN 835625-62-2 CAPLUS  
CN Methanone, [2-chloro-4-[(2,4-difluorophenyl)amino]phenyl][5-(3-hydroxy-1-propen-1-yl)-2-methylphenyl]- (CA INDEX NAME)




RN 835625-63-3 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(2-nitrophenyl)amino]benzoyl]-N-(2-hydroxyethyl)-4-methyl- (CA INDEX NAME)



RN 835625-64-4 CAPLUS  
CN Benzamide, 3-[4-[(4-bromo-2-nitrophenyl)amino]benzoyl]-N-(2-hydroxyethyl)-4-methyl- (CA INDEX NAME)




RN 835625-65-5 CAPLUS  
CN Benzamide, 3-[2-chloro-4-[(2-nitrophenyl)amino]benzoyl]-N-(2-methoxyethyl)-4-methyl- (CA INDEX NAME)




RN 835625-66-6 CAPLUS

CN Benzoic acid, 3-[2-chloro-4-[(4-fluorophenyl)amino]benzoyl]-4-methoxy-  
(CA INDEX NAME)




RN 835625-67-7 CAPLUS

CN Benzoic acid, 3-[2-chloro-4-(phenylamino)benzoyl]-4-methoxy- (CA INDEX  
NAME)



RN 835625-68-8 CAPLUS

CN Methanone, [2-chloro-4-[(2-nitrophenyl)amino]phenyl][2-methyl-4-[2-  
[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]phenyl]- (CA INDEX NAME)




IT 835625-69-9P, [4-(4-Bromo-2-nitrophenylamino)-2-chlorophenyl][2-methyl-4-[2-[(tetrahydropyran-2-yl)oxyl]ethoxy]phenyl]methanone  
 835625-70-2P, [4-(4-Bromo-2-nitrophenylamino)-2-chlorophenyl][2-methyl-4-[3-[(tetrahydropyran-2-yl)oxyl]propoxy]phenyl]methanone  
 835625-71-3P, [4-(4-Bromo-2-nitrophenylamino)-2-chlorophenyl][4-(2-fluoroethoxy)-2-methylphenyl]methanone 835625-72-4P,  
 [4-(4-Bromo-2-nitrophenylamino)-2-chlorophenyl][4-(2-methoxyethoxy)-2-methylphenyl]methanone 835625-73-5P, [2-Chloro-4-(2-nitrophenylamino)phenyl][2-fluoro-5-[2-(morpholin-4-yl)ethoxy]phenyl]methanone 835625-74-6P, [2-Chloro-4-(2-nitrophenylamino)phenyl][5-[2,2-dimethyl-[1,3]dioxolan-4-yl)methoxy]-2-fluorophenyl]methanone  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 $\alpha$  MAP kinase inhibitor; preparation of aminobenzophenones as inhibitors of IL-1 $\beta$  and TNF- $\alpha$  production for treating inflammatory diseases or conditions)


RN 835625-69-9 CAPLUS

CN Methanone, [4-[(4-bromo-2-nitrophenyl)amino]-2-chlorophenyl][2-methyl-4-[2-[(tetrahydro-2H-pyran-2-yl)oxyl]ethoxy]phenyl]- (CA INDEX NAME)




RN 835625-70-2 CAPLUS

CN Methanone, [4-[(4-bromo-2-nitrophenyl)amino]-2-chlorophenyl][2-methyl-4-[3-[(tetrahydro-2H-pyran-2-yl)oxyl]propoxy]phenyl]- (CA INDEX NAME)




RN 835625-71-3 CAPLUS

CN Methanone, [4-[(4-bromo-2-nitrophenyl)amino]-2-chlorophenyl][4-(2-fluoroethoxy)-2-methylphenyl]- (CA INDEX NAME)




RN 835625-72-4 CAPLUS

CN Methanone, [4-(4-bromo-2-nitrophenyl)amino]-2-chlorophenyl][4-(2-methoxyethoxy)-2-methylphenyl]- (CA INDEX NAME)




RN 835625-73-5 CAPLUS

CN Methanone, [2-chloro-4-[(2-nitrophenyl)amino]phenyl][2-fluoro-5-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)




RN 835625-74-6 CAPLUS

CN Methanone, [2-chloro-4-[(2-nitrophenyl)amino]phenyl][5-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-2-fluorophenyl]- (CA INDEX NAME)



RN 835625-75-7 CAPLUS

CN Methanone, [2-chloro-4-[(2-nitrophenyl)amino]phenyl][5-(2,3-dihydroxypropoxy)-2-fluorophenyl]- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:546473 CAPLUS  
 DOCUMENT NUMBER: 141:106279  
 TITLE: Preparation of aminobenzophenones for use in the treatment of inflammatory diseases  
 INVENTOR(S): Ottosen, Erik Rytter; Bjorkling, Fredrik; Dannacher, Heinz Wilhelm  
 PATENT ASSIGNEE(S): Leo Pharma A/S, Den.  
 SOURCE: PCT Int. Appl., 59 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056762	A2	20040708	WO 2003-DK900	20031219
WO 2004056762	A3	20040812		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2510711	A1	20040708	CA 2003-2510711	20031219
AU 2003287917	A1	20040714	AU 2003-287917	20031219
EP 1583735	A2	20051012	EP 2003-779757	20031219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017445	A	20051116	BR 2003-17445	20031219
CN 1753861	A	20060329	CN 2003-80109859	20031219
JP 2006510688	T	20060330	JP 2004-561082	20031219
ZA 2005004720	A	20060830	ZA 2005-4720	20050609
MX 2005PA06435	A	20050908	MX 2005-PA6435	20050615
US 20060058380	A1	20060316	US 2005-539602	20050617
NO 2005003562	A	20050720	NO 2005-3562	20050720

PRIORITY APPLN. INFO.:

US 2002-434798P


P 20021220

OTHER SOURCE(S):

MARPAT 141:106279

W 20031219

GI




**AB** Aminobenzophenones I [R1 = halogen, OH, SH, CF3, aminoalkyl, alkenyl, alkoxy, alkylthio, alkylamino, CN; R2, R4 = H, halogen, OH, SH, CF3, aminoalkyl, alkenyl, alkoxy, alkylthio, alkylamino, CN, CONH2, alkyl, alkenyl, alkoxy, alkylthio, alkoxy carbonyl; R5, R6 = H, alkyl, alkenyl; R7 = (un)substituted alkyl, cycloalkyl, alkenyl, heterocyclic, alkynyl] were prepared for use as prodrugs for cytokine inhibitors in treating inflammatory diseases. Thus, (E)-3,4-C1(2-MeC6H4CO)C6H3N(C6H3MeF-2,4)CO2CHMeO2CCH:CHMe (II) was obtained from 3,4-C1(2-MeC6H4CO)C6H3NH(C6H3MeF-2,4) by reaction with ClCO2CHMeCl, followed by (E)-MeCH:CHCO2NBu4. II had IC50 for inhibition of IL-1 $\beta$  of 7.9 nM.

**IT** 720685-90-5

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of aminobenzophenones for use in the treatment of inflammatory diseases)

**RN** 720685-90-5 CAPPLUS

**CN** Methanone, [2-chloro-4-[(4-fluoro-2-methylphenyl)amino]phenyl](4-chloro-2-methylphenyl)- (CA INDEX NAME)


**IT** 720685-91-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of aminobenzophenones for use in the treatment of inflammatory diseases)

**RN** 720685-91-6 CAPPLUS

**CN** Carbamic acid, [3-chloro-4-(4-chloro-2-methylbenzoyl)phenyl](4-fluoro-2-

methylphenyl)-, 1-chloroethyl ester (9CI) (CA INDEX NAME)




IT 720685-46-1P 720685-48-3P 720685-58-5P  
720685-77-8P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of aminobenzophenones for use in the treatment of inflammatory diseases)


RN 720685-46-1 CAPLUS

CN Butanoic acid, 1-[(3-chloro-4-(4-chloro-2-methylbenzoyl)phenyl)(4-fluoro-2-methylphenyl)amino]carbonyloxyethyl ester (CA INDEX NAME)




RN 720685-48-3 CAPLUS

CN Propanoic acid, 3-methoxy-, 1-[(3-chloro-4-(4-chloro-2-methylbenzoyl)phenyl)(4-fluoro-2-methylphenyl)amino]carbonyloxyethyl ester (CA INDEX NAME)




RN 720685-58-5 CAPLUS

CN Propanoic acid, 2-hydroxy-2-methyl-, 1-[{[3-chloro-4-(4-chloro-2-methylbenzoyl)phenyl](4-fluoro-2-methylphenyl)amino]carbonyloxy]ethyl ester (CA INDEX NAME)



RN 720685-77-8 CAPLUS



CN 3-Pyridinecarboxylic acid, 1-[{[3-chloro-4-(4-chloro-2-methylbenzoyl)phenyl](4-fluoro-2-methylphenyl)amino]carbonyloxy]ethyl ester (CA INDEX NAME)



ACCESSION NUMBER: 2002:814087 CAPLUS  
 DOCUMENT NUMBER: 137:325234  
 TITLE: Preparation of aminophenyl (hetero)aryl ketones as p38 MAP kinase inhibitors for treatment of inflammatory diseases or conditions  
 INVENTOR(S): Havez, Sophie Elisabeth  
 PATENT ASSIGNEE(S): Leo Pharma A/S, Den.  
 SOURCE: PCT Int. Appl., 69 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083622	A2	20021024	WO 2002-DK236	20020410
WO 2002083622	A3	20031113		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002338286	A1	20021028	AU 2002-338286	20020410
US 20030073832	A1	20030417	US 2002-118942	20020410
PRIORITY APPLN. INFO.:			US 2001-282494P	P 20010410
			WO 2002-DK236	W 20020410

OTHER SOURCE(S): MARPAT 137:325234  
 GI



AB Title compds. I [wherein R1 = (un)substituted heteroaryl; X = O, S, N(OH), or NR8; R8 = H or alkyl; R2 = H, halo(alkyl), hydroxy(alkyl), SH, CN, NO2, (cyclo)alkyl, alkenyl, alkynyl, aralkyl, alkylaryl, (ar)alkoxy, alkylthio, alkoxy carbonyl, alkyl carbonyl amino, alkyl carboxy, alkyl carbonyl, NR6R7, or CONR6R7; R3 = H, (cyclo)alkyl, (cyclo)alkenyl, alkynyl, CO2H, or aryl; A = (hetero)aryl; R4 = H, halo(alkyl), hydroxy(alkyl), SH, CN, CO2H, NO2, (cyclo)alkyl, (cyclo)alkenyl, alkynyl, heterocycloalkyl, (hetero)aryl, aralkyl, alkylaryl, (ar)alkoxy, alkylthio, alkoxy carbonyl,

alkylcarbonylamino, aminocarboaminoalkyl, aminosulfonyl, alkylsulfonylamino, alkylcarboxy, alkoxycarboxy, alkylsulfonyloxy, alkoxsulfonyl, alkylcarbonyl, NR6R7, or CONR6R7; R5 = H, halo(alkyl), hydroxy(alkyl), SH, CN, CO2H, carbamoyl, NH2, NO2, (cyclo)alkyl, (cyclo)alkenyl, alkynyl, heterocycloalkyl, (hetero)aryl, aralkyl, alkylaryl, (ar)alkoxy, alkylthio, alkoxy carbonyl, alkylcarbonylamino, aminocarboaminoalkyl, aminosulfonyl, alkylsulfonylamino, alkylcarboxy, alkoxy carboxy, alkylsulfonyloxy, alkoxsulfonyl, alkylcarbonyl, NR6R7, or CONR6R7; R6 and R7 = independently H, alkyl, aryl, etc.; or pharmaceutically acceptable salts, hydrates, solvates, or esters thereof] were prepared as inhibitors of MAP kinases, in particular the p38 MAP kinase. For example, 2-bromo-3-chlorothiophene was coupled with 2-chloro-4-nitrobenzoyl chloride to give 2-chloro-4-nitrophenyl 3-chloro-2-thienyl ketone (44%), which was reduced to the amine (95%). Addition of 2-bromotoluene afforded II (31%). The latter displayed potent inhibitory activity against p38 $\alpha$  MAP kinase with IC50 of 93.3 nM and inhibited production of IL-1 $\beta$ , TNF- $\alpha$ , and PMN-superoxide with IC50 values of 72 nM, 17 nM, and 6.3 nM, resp. Thus, I and compns. of I with other active components are useful as antiinflammatory agents in the prophylaxis or treatment of inflammatory diseases or conditions (no data).


IT 473423-06-2P, [3-Methyl-2-benzothienyl][4-(2-tolylamino)-2-chlorophenyl]ketone

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 MAP kinase inhibitor; preparation of aminophenyl (hetero)aryl ketones as p38 MAP kinase inhibitors by coupling (halo)heterocycles with nitrobenzoyl chlorides followed by reduction)

RN 473423-06-2 CAPLUS

CN Methanone, [2-chloro-4-[(2-methylphenyl)amino]phenyl][3-methyl-5-(2-thienyl)phenyl]- (CA INDEX NAME)





L4 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2002:658099 CAPLUS  
 DOCUMENT NUMBER: 137:201301  
 TITLE: Preparation of isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones as JNK inhibitors  
 INVENTOR(S): Sakata, Steven T.; Raymon, Heather K.  
 PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 196 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066450	A2	20020829	WO 2002-US4283	20020213
WO 2002066450	A3	20021205		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20030073732	A1	20030417	US 2002-71390	20020207
US 6987184	B2	20060117		
CA 2438312	A1	20020829	CA 2002-2438312	20020213
AU 2002251936	A1	20020904	AU 2002-251936	20020213
EP 1363891	A2	20031126	EP 2002-720975	20020213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004526711	T	20040902	JP 2002-565966	20020213
NZ 528034	A	20051223	NZ 2002-528034	20020213
US 20060004080	A1	20060105	US 2005-159592	20050622
US 7354947	B2	20080408		
PRIORITY APPLN. INFO.:			US 2001-269013P	P 20010215
			US 2002-71390	A 20020207
			WO 2002-US4283	W 20020213

OTHER SOURCE(S):  
GI

MARPAT 137:201301




AB The title compds. [(un)substituted I; R0 = CH2, SO, O, SO2, S], useful for treating or preventing a disorder alleviated by inhibiting Jun N-terminal kinase (JNK), were prepared. Thus, treating 1-aminoanthraquinone with NH4SCN in the presence of H2SO4 in DMSO followed by heating the thiocyanate-addition intermediate in liquid ammonia in a bomb to 140° for 5 h afforded II which showed IC50 of 1 μM for JNK2 and 400 nM for JNK3.

IT 56794-82-2P 56795-04-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones

as JNK inhibitors)  
RN 56794-82-2 CAPLUS  
CN 6H-Antra[9,1-cd]isothiazol-6-one, 7,7'-[{4-[4-[(6-oxo-6H-antra[9,1-cd]isothiazol-7-yl)amino]benzoyl]-1,3-phenylene}diimino]bis- (9CI) (CA INDEX NAME)



RN 56795-04-1 CAPLUS  
CN 6H-Antra[9,1-cd]isothiazol-6-one, 7,7'-[{5-[2,4-bis[(6-oxo-6H-antra[9,1-cd]isothiazol-7-yl)amino]benzoyl]-2-methyl-1,3-phenylene}diimino]bis- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2002:449531 CAPLUS  
 DOCUMENT NUMBER: 137:37646  
 TITLE: Dermal anti-inflammatory composition containing a lipophilic anti-inflammatory agent  
 INVENTOR(S): Hedeman, Hanne; Refer, Pia Klie; Didriksen, Erik Johannes; Fullerton, Ann Vivian; Aaes, Helle; Groth, Lotte  
 PATENT ASSIGNEE(S): Leo Pharmaceutical Products Ltd. A/S, Den.  
 SOURCE: PCT Int. Appl., 37 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002045752	A2	20020613	WO 2001-DK813	20011207
WO 2002045752	A3	20020926		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20020165286	A1	20021107	US 2001-3709	20011206
AU 200220533	A	20020618	AU 2002-20533	20011207
PRIORITY APPLN. INFO.:			US 2000-251882P	P 20001208
			WO 2001-DK813	W 20011207

AB A pharmaceutical composition for dermal application comprises a lipophilic anti-inflammatory compound and a pharmaceutically acceptable vehicle comprising a lipophilic excipient capable of solubilizing the anti-inflammatory compound and targeting said compound to the pilosebaceous ducts on application of the composition on the skin. The composition may be used in


the treatment of dermal inflammatory conditions, in particular acne. A composition contained 2-chloro-4-(4-fluoro-2-methylphenylamino)-2'-methylbenzophenone test substance and the following vehicles: Labrasol, Cetiol B, Arlamol DOA, Miglycol 812, Miglycol 840, DPPG, Pemulen TR1, Pemulen TR2, Span 80, ethanol, water, and Plurol Isostearique.

IT 321351-02-4 321351-03-5 321351-04-6  
 321351-06-8 321351-07-9 321351-08-0  
 321351-09-1 321359-20-0 321359-21-1  
 321377-90-6 321377-91-7 321377-92-8  
 321377-95-1 321377-96-2 321378-16-9  
 344458-04-4

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (dermal anti-inflammatory composition containing a lipophilic anti-inflammatory agent)


RN 321351-02-4 CAPLUS

CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](2,3-dimethylphenyl)- (CA INDEX NAME)




RN 321351-03-5 CAPLUS

CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](4-butyl-2-methylphenyl)- (CA INDEX NAME)




RN 321351-04-6 CAPLUS

CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](4-chloro-2-methylphenyl)- (CA INDEX NAME)




RN 321351-06-8 CAPLUS


CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](2,5-dimethylphenyl)- (CA INDEX NAME)




RN 321351-07-9 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](3-chloro-2-methylphenyl)- (CA INDEX NAME)



RN 321351-08-0 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-fluorophenyl](4-methoxy-2-methylphenyl)- (CA INDEX NAME)




RN 321351-09-1 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](4-ethoxy-2-methylphenyl)- (CA INDEX NAME)




RN 321359-20-0 CAPLUS

CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](2,4,5-trimethylphenyl)- (CA INDEX NAME)




RN 321359-21-1 CAPLUS

CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](4-fluoro-2-methylphenyl)- (CA INDEX NAME)




RN 321377-90-6 CAPLUS

CN Methanone, [4-[(2-aminophenyl)amino]-2-chlorophenyl](2-chloro-4-methoxyphenyl)- (CA INDEX NAME)




RN 321377-91-7 CAPLUS


CN Methanone, [4-[(2-aminophenyl)amino]-2-chlorophenyl](2,3-dichloro-4-methoxyphenyl)- (CA INDEX NAME)




RN 321377-92-8 CAPLUS  
CN Methanone, [4-[(2-aminophenyl)amino]-2-chlorophenyl](2,6-dichloro-4-methoxyphenyl)- (CA INDEX NAME)




RN 321377-95-1 CAPLUS  
CN Methanone, [4-[(2-aminophenyl)amino]-2-chlorophenyl](2-chloro-4-hydroxyphenyl)- (CA INDEX NAME)




RN 321377-96-2 CAPLUS  
CN Methanone, [4-[(2-aminophenyl)amino]-2-chlorophenyl](2,4-dichloro-6-hydroxyphenyl)- (CA INDEX NAME)



RN 321378-16-9 CAPLUS  
CN Methanone, [4-[(2-aminophenyl)amino]-2-chlorophenyl](3-fluoro-2-methylphenyl)- (CA INDEX NAME)




RN 344458-04-4 CAPLUS  
 CN Methanone, [2-chloro-4-[(4-fluoro-2-methylphenyl)amino]phenyl](3-fluoro-2-methylphenyl)- (CA INDEX NAME)



L4 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2001:868420 CAPLUS  
 DOCUMENT NUMBER: 136:5794  
 TITLE: Preparation of benzophenones as inhibitors of IL-1 $\beta$  and TNF- $\alpha$   
 INVENTOR(S): Hornerman, Anne Marie  
 PATENT ASSIGNEE(S): Leo Pharmaceutical Products Ltd. A/S, Den.  
 SOURCE: PCT Int. Appl., 80 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001090074	A2	20011129	WO 2001-DK346	20010518
WO 2001090074	A3	20020502		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2408727	A1	20011129	CA 2001-2408727	20010518
AU 2001060081	A	20011203	AU 2001-60081	20010518
EP 1289958	A2	20030312	EP 2001-933642	20010518
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001011034	A	20030617	BR 2001-11034	20010518
HU 2003001932	A2	20030929	HU 2003-1932	20010518
HU 2003001932	A3	20070928		
JP 2003534327	T	20031118	JP 2001-586263	20010518
AU 2001260081	B2	20050728	AU 2001-260081	20010518
RU 2270194	C2	20060220	RU 2002-134487	20010518
US 20020016347	A1	20020207	US 2001-860492	20010521
US 6432962	B2	20020813		

MX 2002PA11376 HK 1055949 PRIORITY APPLN. INFO.:	A 20040226 A1 20060804	MX 2002-PA11376 HK 2003-108182 US 2000-205579P WO 2001-DK346	20021118 20031112 P 20000522 W 20010518
OTHER SOURCE(S): GI	MARPAT 136:5794		




**AB** The title compds. [I; R1 = halo, haloalkyl, OH, etc.; R2 = H, halo, haloalkyl, etc.; R3 = H, halo, haloalkyl, etc.; R4 = H, alkyl, aryl, etc.; R5 = (un)substituted heteroarom. mono- or bicyclic ring system comprising 1-4 heteroatoms; X = O, S, NOH, NR11; R11 = H, alkyl] which inhibit interleukin-1 $\beta$  and TNF- $\alpha$  and may therefore be useful in the therapy of inflammatory diseases and conditions, were prepared and formulated. E.g., a multi-step synthesis of I [R1 = Me; R2 = H; R3 = 2-Cl; R4 = 4-isouquinolyl; R5 = H; X = O] which showed IC50 of 31 nM, 5.0 nM, 15 nM, and 12.8 nM against IL-1 $\beta$ , TNF- $\alpha$ , PMN-superoxide production in vitro, and against p38 $\alpha$  MAP kinase, resp., was given.

**IT** 376626-45-8P 376626-46-9P 376626-47-0P  
**RL:** PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of benzophenones as inhibitors of IL-1 $\beta$  and TNF- $\alpha$ )

**RN** 376626-45-8 CAPLUS


**CN** Methanone, [2-chloro-4-[(1-methyl-1H-indol-7-yl)amino]phenyl](4-chloro-2-methylphenyl)- (CA INDEX NAME)



RN 376626-46-9 CAPLUS  
CN Methanone, [2-chloro-4-[(1-methyl-1H-indol-7-yl)amino]phenyl](2,4,5-trimethylphenyl)- (CA INDEX NAME)



RN 376626-47-0 CAPLUS  
CN Methanone, [2-chloro-4-[(1-methyl-1H-indol-7-yl)amino]phenyl](2,5-dimethylphenyl)- (CA INDEX NAME)



L4 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:435023 CAPLUS

DOCUMENT NUMBER: 135:45992

TITLE: Aminobenzophenones as inhibitors of IL-1 $\beta$  and TNF- $\alpha$ 

INVENTOR(S): Ottosen, Erik Ryter

PATENT ASSIGNEE(S): Leo Pharmaceutical Products Ltd. A/s (Lovens Kemiske Fabrik Produktionsaktieselskab), Den.

SOURCE: PCT Int. Appl., 57 pp.

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001042189	A1	20010614	WO 2000-DK653	20001129
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NC, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2393312	A1	20010614	CA 2000-2393312	20001129
BR 2000016164	A	20020813	BR 2000-16164	20001129
EP 1237845	A1	20020911	EP 2000-979457	20001129
EP 1237845	B1	20070523		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2002003813	A2	20030328	HU 2002-3813	20001129
HU 2002003813	A3	20080328		
JP 2003516377	T	20030513	JP 2001-543491	20001129

NZ 519172	A	20040326	NZ 2000-519172	20001129
AU 776395	B2	20040909	AU 2001-16935	20001129
RU 2260422	C2	20050920	RU 2002-118113	20001129
AT 362912	T	20070615	AT 2000-979457	20001129
ES 2287040	T3	20071216	ES 2000-979457	20001129
US 20030013770	A1	20030116	US 2001-787532	20010320
US 6541670	B2	20030401		
MX 2002PA05604	A	20040910	MX 2002-PA5604	20020606
HK 1053463	A1	20050909	HK 2003-105831	20030814
PRIORITY APPLN. INFO.:			US 1999-169333P	P 19991206
OTHER SOURCE(S):			WO 2000-DK653	W 20001129
GI				



**AB** Title compds. I are disclosed [wherein: R1 = halo, OH, SH, CF<sub>3</sub>, amino, (C1-3)alkyl, (C2-3)olefinic, (C1-3)alkoxy, (C1-3)alkylthio, (C1-6)alkylamino, (C1-3)alkoxycarbonyl, cyano, CONH<sub>2</sub>, Ph, and NO<sub>2</sub>; R2 = one or more of H, halo, OH, SH, CF<sub>3</sub>, amino, (C1-3)alkyl, (C2-3)olefinic, (C1-3)alkoxy, (C1-3)alkylthio, (C1-6)alkylamino, (C1-3)alkoxycarbonyl, cyano, CONH<sub>2</sub>, Ph, and NO<sub>2</sub>; R3 = one or more of H, halo, OH, SH, CF<sub>3</sub>, cyano, CO<sub>2</sub>H, carbamoyl, (C1-10)alkyl, (C2-10)olefinic, (C3-8)monocyclic hydrocarbon, (C1-10)alkoxy, (C1-10)alkylthio, (C1-10)alkoxycarbonyl, and Ph; R4 = H, (C1-6)alkyl, (C2-6)olefinic, or (C3-6)monocyclic hydrocarbon; R5 = one or more of H and R1; X = O, S, or N-OH; and salts thereof with pharmaceutically acceptable acids, hydrates and solvates; with 9 specific exclusions]. The compds. are cytokine inhibitors, and may be used in the prophylaxis or treatment of a variety of inflammatory and other diseases. They may be administered in combination with a variety of other drugs and drug classes. Examples include preps. of 46 I [X = O] and 18 precursors. Claims cover these compds. I and the analogous I [X = S, N-OH]. For instance, 2-bromotoluene was lithiated, converted to an organozinc compound, and coupled with 2-chloro-4-nitrobenzoyl chloride under Pd(0) catalysis to


give 2-chloro-2'-methyl-4-nitrobenzophenone. This was reduced with SnCl<sub>2</sub> in EtOH to give the amine, which was coupled with 2-bromotoluene in the presence of NaOBu-t, Pd2(dba)3, and BINAP, to give title compound II. This compound inhibited IL-1 $\beta$ , TNF- $\alpha$ , and PMN-superoxide production with IC<sub>50</sub> values of 13, 4.0, and 6.3 nM, resp.

IT 344458-04-4P 344458-09-9P 344458-10-2P  
 344458-11-3P 344458-13-5P 344458-18-0P  
 344458-20-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of aminobenzophenones as inhibitors of IL-1 $\beta$  and TNF- $\alpha$ )


RN 344458-04-4 CAPLUS

CN Methanone, [2-chloro-4-[(4-fluoro-2-methylphenyl)amino]phenyl](3-fluoro-2-methylphenyl)- (CA INDEX NAME)




RN 344458-09-9 CAPLUS

CN Methanone, [4-[(4-bromo-2-methylphenyl)amino]-2-chlorophenyl](4-methoxy-2-methylphenyl)- (CA INDEX NAME)




RN 344458-10-2 CAPLUS


CN Methanone, [4-[(4-bromo-2-methylphenyl)amino]-2-chlorophenyl](4-chloro-2-methylphenyl)- (CA INDEX NAME)




RN 344458-11-3 CAPLUS  
CN Methanone, [4-[(4-bromo-2-methylphenyl)amino]-2-chlorophenyl](4-fluoro-2-methylphenyl)- (CA INDEX NAME)




RN 344458-13-5 CAPLUS  
CN Methanone, [4-[(4-bromo-2-methylphenyl)amino]-2-chlorophenyl](2,5-dimethylphenyl)- (CA INDEX NAME)



RN 344458-18-0 CAPLUS  
CN Methanone, [4-[(4-bromo-2-methylphenyl)amino]-2-chlorophenyl](4-ethoxy-2-methylphenyl)- (CA INDEX NAME)



RN 344458-20-4 CAPLUS  
CN Methanone, [4-[(4-bromo-2-methylphenyl)amino]-2-chlorophenyl](3-chloro-2-methylphenyl)- (CA INDEX NAME)





REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2001:63961 CAPLUS  
 DOCUMENT NUMBER: 134:115759  
 TITLE: Preparation of aminobenzophenones as inhibitors of IL-1 $\beta$  and TNF- $\alpha$   
 INVENTOR(S): Ottosen, Erik Rytter  
 PATENT ASSIGNEE(S): Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktie, Den.  
 SOURCE: PCT Int. Appl., 39 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005751	A1	20010125	WO 2000-DK387	20000711
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2379293	A1	20010125	CA 2000-2379293	20000711
EP 1210325	A1	20020605	EP 2000-943701	20000711
EP 1210325	B1	20041006		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
HU 2002001913	A2	20020128	HU 2002-1913	20000711
HU 2002001913	A3	20021128		
AU 768878	B2	20040108	AU 2000-58070	20000711
AT 278663	T	20040105	AT 2000-943701	20000711
PT 1210325	T	20050131	PT 2000-943701	20000711
RU 2247719	C2	20050310	RU 2002-103865	20000711
ES 2228556	T3	20050416	ES 2000-943701	20000711
US 6750253	B1	20040615	US 2002-30970	20020222
HK 1048464	A1	20060901	HK 2003-100584	20030123
PRIORITY APPLN. INFO.:			US 1999-144062P	P 19990716
			WO 2000-DK387	W 20000711

OTHER SOURCE(S):  
GI

MARPAT 134:115759



AB The title compds. [I; R1, R2 = halo, OH, SH, etc.; R3 = H, halo, OH, etc.; R4 = H, alkyl, allyl; Q = a bond, SO<sub>2</sub>, CR<sub>6</sub>R<sub>7</sub>O:C:O (wherein R6, R7 = H, CF<sub>3</sub>, alkyl); Y = alkyl, alkenyl, cycloalkyl, etc.; X = O, S] which are able to inhibit the production of IL-1 $\beta$ , TNF- $\alpha$  and PMN-superoxide, were prepared and formulated. Thus, reacting 4-(2-aminophenylamino)-2-chloro-2'-methylbenzophenone with cyclohexyl isocyanate in EtOAc afforded the urea II which showed IC<sub>50</sub> of 13 nM and of 5.0 nM against IL-1 $\beta$  and TNF- $\alpha$  production, resp.

IT 321438-21-5P 321438-22-6P 321438-23-7P


321438-24-8P 321438-26-0P 321438-27-1P

321438-28-2P 321438-29-3P 321438-30-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of aminobenzophenones as inhibitors of IL-1 $\beta$  and TNF- $\alpha$ )


RN 321438-21-5 CAPLUS

CN Urea, N-[5-bromo-2-[(4-(4-butyl-2-methylbenzoyl)-3-chlorophenyl)amino]phenyl]-N'-ethyl- (CA INDEX NAME)




RN 321438-22-6 CAPLUS

CN Urea, N-[5-bromo-2-[(3-chloro-4-(2,5-dimethylbenzoyl)phenyl)amino]phenyl]-N'-ethyl- (CA INDEX NAME)




RN 321438-23-7 CAPLUS

CN Urea, N-[5-bromo-2-[(3-chloro-4-(3-chloro-2-methylbenzoyl)phenyl)amino]phenyl]-N'-ethyl- (CA INDEX NAME)




RN 321438-24-8 CAPLUS

CN Urea, N-[5-bromo-2-[(3-chloro-4-(4-ethoxy-2-methylbenzoyl)phenyl)amino]phenyl]-N'-ethyl- (CA INDEX NAME)




RN 321438-26-0 CAPLUS

CN Urea, N-[5-bromo-2-[(3-chloro-4-(4-chloro-2-methylbenzoyl)phenyl)amino]phenyl]-N'-ethyl- (CA INDEX NAME)




RN 321438-27-1 CAPLUS

CN Urea, N-[5-bromo-2-[(3-chloro-4-(2,3-dimethylbenzoyl)phenyl)amino]phenyl]-N'-ethyl- (CA INDEX NAME)




RN 321438-28-2 CAPLUS


CN Urea, N-[5-bromo-2-[(3-fluoro-4-(4-methoxy-2-methylbenzoyl)phenyl)amino]phenyl]-N'-ethyl- (CA INDEX NAME)




RN 321438-29-3 CAPLUS  
CN Urea, N-[5-bromo-2-[(3-chloro-4-(2,4,5-trimethylbenzoyl)phenyl]amino]phenyl]-N'-ethyl- (CA INDEX NAME)




RN 321438-30-6 CAPLUS  
CN Urea, N-[5-bromo-2-[(3-chloro-4-(4-fluoro-2-methylbenzoyl)phenyl]amino]phenyl]-N'-ethyl- (CA INDEX NAME)




IT 321351-02-4 321351-03-5 321351-04-6  
321351-06-8 321351-07-9 321351-08-0  
321351-09-1 321359-20-0 321359-21-1  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of aminobenzophenones as inhibitors of IL-1 $\beta$  and  
TNF- $\alpha$ )  
RN 321351-02-4 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](2,3-dimethylphenyl)- (CA INDEX NAME)




RN 321351-03-5 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](4-butyl-2-methylphenyl)- (CA INDEX NAME)




RN 321351-04-6 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](4-chloro-2-methylphenyl)- (CA INDEX NAME)




RN 321351-06-8 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](2,5-dimethylphenyl)- (CA INDEX NAME)




RN 321351-07-9 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](3-chloro-2-methylphenyl)- (CA INDEX NAME)




RN 321351-08-0 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-fluorophenyl](4-methoxy-2-methylphenyl)- (CA INDEX NAME)




RN 321351-09-1 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](4-ethoxy-2-methylphenyl)- (CA INDEX NAME)



RN 321359-20-0 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](2,4,5-trimethylphenyl)- (CA INDEX NAME)



RN 321359-21-1 CAPLUS  
 CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](4-fluoro-2-methylphenyl)- (CA INDEX NAME)





REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2001:63959 CAPLUS  
 DOCUMENT NUMBER: 134:115755  
 TITLE: Preparation of aminobenzophenones as inhibitors of IL-1 $\beta$  and TNF- $\alpha$   
 INVENTOR(S): Ottosen, Erik Rytter; Dannacher, Heinz Wilhelm  
 PATENT ASSIGNEE(S): Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktie, Den.  
 SOURCE: PCT Int. Appl., 45 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005749	A1	20010125	WO 2000-DK386	20000711
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2379286	A1	20010125	CA 2000-2379286	20000711
AU 2000058069	A	20010205	AU 2000-58069	20000711
AU 768512	B2	20031218		
EP 1202959	A1	20020508	EP 2000-943700	20000711
EP 1202959	B1	20040929		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
HU 2002001911	A2	20021028	HU 2002-1911	20000711
HU 2002001911	A3	20021128		
NZ 516825	A	20040528	NZ 2000-516825	20000711
AT 277897	T	20041015	AT 2000-943700	20000711

RU 2240995	C2	20041127	RU 2002-103876	20000711
PT 1202959	T	20050131	PT 2000-943700	20000711
ES 2230118	T3	20050501	ES 2000-943700	20000711
US 6897236	B1	20050524	US 2001-30941	20000711
HK 1048303	A1	20050311	HK 2003-100556	20030123
PRIORITY APPLN. INFO.:			US 1999-144063P	P 19990716
			WO 2000-DK386	W 20000711

OTHER SOURCE(S): MARPAT 134:115755  
GI




- AB The title compds. [I; R1-R3 = H, halo, OH, etc.; R4 = H, alkyl, allyl; Q = a bond, CR6R7CO (wherein R6, R7 = H, CF3, alkyl); Y = alkyl, alkenyl, cycloalkyl, etc.; X = O, S] which are able to inhibit the production of IL-1 $\beta$ , TNF- $\alpha$  and PMN-superoxide production, were prepared and formulated. Thus, reacting 4-(2-aminophenylamino)-2-chloro-2'-methylbenzophenone with Ph chloroformate in the presence of N-Et diisopropylamine in CH2Cl2 afforded II which showed IC50 of 50 nM and of 10 nM against IL-1 $\beta$  and TNF $\alpha$  production, resp.
- IT 321359-01-7P 321359-02-8P 321359-03-9P  
 321359-05-1P 321359-06-2P 321359-07-3P  
 321359-08-4P 321359-09-5P 321359-10-8P  
 RL: BAC (Biological activity or effector, except adverse), BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of aminobenzophenones as inhibitors of IL-1 $\beta$  and TNF- $\alpha$ )
- RN 321359-01-7 CAPLUS  
 CN Carbanic acid, [5-bromo-2-[{3-chloro-4-(2,3-dimethylbenzoyl)phenyl}amino]phenyl]-, cyclopentyl ester (9CI) (CA INDEX NAME)




RN 321359-02-8 CAPLUS

CN Carbamic acid, [5-bromo-2-[(4-(4-butyl-2-methylbenzoyl)-3-chlorophenyl)amino]phenyl]-, cyclopentyl ester (9CI) (CA INDEX NAME)




RN 321359-03-9 CAPLUS

CN Carbamic acid, [5-bromo-2-[(3-chloro-4-(4-chloro-2-methylbenzoyl)phenyl)amino]phenyl]-, cyclopentyl ester (9CI) (CA INDEX NAME)




RN 321359-05-1 CAPLUS

CN Carbamic acid, [5-bromo-2-[(3-chloro-4-(2,4,5-trimethylbenzoyl)phenyl)amino]phenyl]-, cyclopentyl ester (9CI) (CA INDEX NAME)




RN 321359-06-2 CAPLUS

CN Carbamic acid, [5-bromo-2-[[3-chloro-4-(4-fluoro-2-methylbenzoyl)phenyl]amino]phenyl]-, cyclopentyl ester (9CI) (CA INDEX NAME)




RN 321359-07-3 CAPLUS

CN Carbamic acid, [5-bromo-2-[[3-chloro-4-(2,5-dimethylbenzoyl)phenyl]amino]phenyl]-, cyclopentyl ester (9CI) (CA INDEX NAME)




RN 321359-08-4 CAPLUS

CN Carbamic acid, [5-bromo-2-[[3-chloro-4-(3-chloro-2-methylbenzoyl)phenyl]amino]phenyl]-, cyclopentyl ester (9CI) (CA INDEX NAME)




RN 321359-09-5 CAPLUS

CN Carbanic acid, [5-bromo-2-[(3-fluoro-4-(4-methoxy-2-methylbenzoyl)phenyl)amino]phenyl]-, cyclopentyl ester (9CI) (CA INDEX NAME)



RN 321359-10-8 CAPLUS

CN Carbanic acid, [5-bromo-2-[(3-chloro-4-(4-ethoxy-2-methylbenzoyl)phenyl)amino]phenyl]-, cyclopentyl ester (9CI) (CA INDEX NAME)



IT 321351-02-4 321351-03-5 321351-04-6

321351-06-8 321351-07-9 321351-08-0

321351-09-1 321359-20-0 321359-21-1


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of aminobenzophenones as inhibitors of IL-1 $\beta$  and TNF- $\alpha$ )

RN 321351-02-4 CAPLUS


CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](2,3-

dimethylphenyl)- (CA INDEX NAME)




RN 321351-03-5 CAPLUS

CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](4-butyl-2-methylphenyl)- (CA INDEX NAME)




RN 321351-04-6 CAPLUS

CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](4-chloro-2-methylphenyl)- (CA INDEX NAME)




RN 321351-06-8 CAPLUS


CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](2,5-dimethylphenyl)- (CA INDEX NAME)




RN 321351-07-9 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](3-chloro-2-methylphenyl)- (CA INDEX NAME)



RN 321351-08-0 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-fluorophenyl](4-methoxy-2-methylphenyl)- (CA INDEX NAME)




RN 321351-09-1 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](4-ethoxy-2-methylphenyl)- (CA INDEX NAME)




RN 321359-20-0 CAPLUS

CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](2,4,5-trimethylphenyl)- (CA INDEX NAME)



RN 321359-21-1 CAPLUS

CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](4-fluoro-2-methylphenyl)- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2001:63956 CAPLUS

DOCUMENT NUMBER: 134:115751

TITLE: Preparation of aminobenzophenones as inhibitors of IL-1 $\beta$  and TNF- $\alpha$ 

INVENTOR(S): Ottosen, Erik Rytter

PATENT ASSIGNEE(S): Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktie, Den.

SOURCE: PCT Int. Appl., 45 pp.  
CODEN: PIXDZ2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005746	A1	20010125	WO 2000-DK385	20000711
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MN, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,				

CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2379273	A1	20010125	CA 2000-2379273	20000711
EP 1210320	A1	20020605	EP 2000-943699	20000711
EP 1210320	B1	20040929		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
HU 2002001846	A2	20021028	HU 2002-1846	20000711
HU 2002001846	A3	20021128		
AU 769138	B2	20040115	AU 2000-58068	20000711
AT 277891	T	20041015	AT 2000-943699	20000711
RU 2239628	C2	20041110	RU 2002-103866	20000711
PT 1210320	T	20050131	PT 2000-943699	20000711
ES 2228555	T3	20050416	ES 2000-943699	20000711
US 6566554	B1	20030520	US 2002-31075	20020222
HK 104/273	A1	20050506	HK 2002-108688	20021129
PRIORITY APPLN. INFO.:			US 1999-144166P	P 19990716
			WO 2000-DK385	W 20000711

OTHER SOURCE(S): MARPAT 134:115751  
GI




- AB** The title compds. [I; R1-R3 = halo, OH, SH, etc.; R4 = H, alkyl, allyl; X = O, S; Q = CO, CS, a bond; Y = alkyl, alkenyl, cycloalkyl, etc.] which are able to inhibit the production of IL-1 $\beta$ , TNF- $\alpha$  and PMN-superoxide, were prepared and formulated. Thus, reacting 4-(2-aminophenylamino)-2-chloro-2'-methylbenzophenone with succinic anhydride in glacial AcOH afforded the aminobenzophenone II which showed IC50 of 200 nM and of 25 nM against IL-1 $\beta$  and TNF- $\alpha$  production, resp.
- IT** 321371-54-4P 321371-56-6P 321371-57-7P  
321371-58-8P 321371-60-2P 321371-61-3P  
321371-62-4P 321371-63-5P 321371-64-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of aminobenzophenones as inhibitors of IL-1 $\beta$  and TNF- $\alpha$ )


RN 321371-54-4 CAPLUS

CN Butanoic acid, 4-[(5-bromo-2-[(3-chloro-4-(4-ethoxy-2-methylbenzoyl)phenyl]amino)phenyl]amino]-4-oxo- (CA INDEX NAME)




RN 321371-56-6 CAPLUS

CN Butanoic acid, 4-[(5-bromo-2-[(3-chloro-4-(2,3-dimethylbenzoyl)phenyl]amino)phenyl]amino]-4-oxo- (CA INDEX NAME)




RN 321371-57-7 CAPLUS

CN Butanoic acid, 4-[(5-bromo-2-[(4-(4-butyl-2-methylbenzoyl)-3-chlorophenyl]amino)phenyl]amino]-4-oxo- (CA INDEX NAME)




RN 321371-58-8 CAPLUS

CN Butanoic acid, 4-[(5-bromo-2-[(3-chloro-4-(4-chloro-2-methylbenzoyl)phenyl]amino)phenyl]amino]-4-oxo- (CA INDEX NAME)




RN 321371-60-2 CAPLUS

CN Butanoic acid, 4-[(5-bromo-2-[(3-chloro-4-(2,4,5-trimethylbenzoyl)phenyl]amino)phenyl]amino]-4-oxo- (CA INDEX NAME)




RN 321371-61-3 CAPLUS

CN Butanoic acid, 4-[(5-bromo-2-[(3-chloro-4-(4-fluoro-2-methylbenzoyl)phenyl]amino)phenyl]amino]-4-oxo- (CA INDEX NAME)




RN 321371-62-4 CAPLUS

CN Butanoic acid, 4-[(5-bromo-2-[(3-chloro-4-(2,5-dimethylbenzoyl)phenyl]amino)phenyl]amino]-4-oxo- (CA INDEX NAME)




RN 321371-63-5 CAPLUS

CN Butanoic acid, 4-[(5-bromo-2-[(3-fluoro-4-(4-methoxy-2-methylbenzoyl)phenyl]amino)phenyl]amino]-4-oxo- (CA INDEX NAME)



RN 321371-64-6 CAPLUS

CN Butanoic acid, 4-[(5-bromo-2-[(3-chloro-4-(3-chloro-2-methylbenzoyl)phenyl]amino)phenyl]amino]-4-oxo- (CA INDEX NAME)



IT 321351-02-4 321351-03-5 321351-04-6

321351-06-8 321351-07-9 321351-08-0


321351-09-1 321359-20-0 321359-21-1

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of aminobenzophenones as inhibitors of IL-1 $\beta$  and TNF- $\alpha$ )

RN 321351-02-4 CAPLUS


CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](2,3-dimethylphenyl)- (CA INDEX NAME)




RN 321351-03-5 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](4-butyl-2-methylphenyl)- (CA INDEX NAME)




RN 321351-04-6 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](4-chloro-2-methylphenyl)- (CA INDEX NAME)




RN 321351-06-8 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](2,5-dimethylphenyl)- (CA INDEX NAME)




RN 321351-07-9 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](3-chloro-2-methylphenyl)- (CA INDEX NAME)




RN 321351-08-0 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-fluorophenyl](4-methoxy-2-methylphenyl)- (CA INDEX NAME)




RN 321351-09-1 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](4-ethoxy-2-methylphenyl)- (CA INDEX NAME)



RN 321359-20-0 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](2,4,5-trimethylphenyl)- (CA INDEX NAME)



RN 321359-21-1 CAPLUS  
 CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](4-fluoro-2-methylphenyl)- (CA INDEX NAME)





REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2001:63955 CAPLUS  
 DOCUMENT NUMBER: 134:115754  
 TITLE: Preparation of aminobenzophenones as inhibitors of IL-1 $\beta$  and TNF- $\alpha$   
 INVENTOR(S): Ottosen, Erik Rytter  
 PATENT ASSIGNEE(S): Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktie, Den.  
 SOURCE: PCT Int. Appl., 32 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005745	A1	20010125	WO 2000-DK388	20000711
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2379319	A1	20010125	CA 2000-2379319	20000711
AU 2000058071	A	20010205	AU 2000-58071	20000711
AU 768816	B2	20040108		

EP 1202957	A1	20020508	EP 2000-943702	20000711
EP 1202957	B1	20040929		
R: AT, BE, CH, IE, SI, LT,	DE, DK, ES, FR, LV, FI, RO, MK,	GB, GR, IT, LI, LU, NL, SE, MC, PT, CY, AL		
HU 2002001909	A2	20021028	HU 2002-1909	20000711
HU 2002001909	A3	20021128		
AT 277889	T	20041015	AT 2000-943702	20000711
RU 2238933	C2	20041027	RU 2002-103867	20000711
PT 1202957	T	20050131	PT 2000-943702	20000711
ES 2228557	T3	20050416	ES 2000-943702	20000711
US 6555710	B1	20030429	US 2002-31071	20020315
HK 1048465	A1	20050408	HK 2003-100589	20030123
PRIORITY APPLN. INFO.:			US 1999-144169P	P 19990716
			WO 2000-DK388	W 20000711

OTHER SOURCE(S): MARPAT 134:115754  
GI




AB The title compds. [I; R1, R2 = halo, OH, SH, etc.; R3 = H, halo, OH, etc.; R4 = H, alkyl, allyl; X = O, S; with the proviso that I does not comprise the compound 2,2,2-trifluoro-N-[2-[3-chloro-4-(2-methylbenzoyl)phenyl]amino]phenyl]acetamide wherein R1 = 2-Me, R2 = 2-Cl, R3, R4 = H, and X = O] which are able to inhibit the production of IL-1 $\beta$ , TNF- $\alpha$  and PMN-superoxide, were prepared and formulated. Thus, reacting 4-[(2-amino-4-bromophenyl)amino]-2-chloro-2'-methylbenzophenone with trifluoroacetic anhydride in the presence of pyridine in CH<sub>2</sub>Cl<sub>2</sub> afforded II which showed IC<sub>50</sub> of 32 nM and of 6.3 nM against IL-1 $\beta$  and TNF- $\alpha$  production, resp.

IT 321350-89-4P 321350-90-7P 321350-91-8P  
321350-93-0P 321350-94-1P 321350-95-2P  
321350-96-3P 321350-98-5P 321350-99-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of aminobenzophenones as inhibitors of IL-1 $\beta$  and TNF- $\alpha$ )


RN 321350-89-4 CAPLUS

CN Acetamide, N-[5-bromo-2-[(3-chloro-4-(2,3-dimethylbenzoyl)phenyl)amino]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 321350-90-7 CAPLUS

CN Acetamide, N-[5-bromo-2-[(4-(4-butyl-2-methylbenzoyl)-3-chlorophenyl)amino]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 321350-91-8 CAPLUS

CN Acetamide, N-[5-bromo-2-[(3-chloro-4-(4-chloro-2-methylbenzoyl)phenyl)amino]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 321350-93-0 CAPLUS

CN Acetamide, N-[5-bromo-2-[(3-chloro-4-(2,5-dimethylbenzoyl)phenyl]amino]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 321350-94-1 CAPLUS

CN Acetamide, N-[5-bromo-2-[(3-chloro-4-(3-chloro-2-methylbenzoyl)phenyl]amino]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 321350-95-2 CAPLUS

CN Acetamide, N-[5-bromo-2-[(3-fluoro-4-(4-methoxy-2-methylbenzoyl)phenyl]amino]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 321350-96-3 CAPLUS


CN Acetamide, N-[5-bromo-2-[(3-chloro-4-(4-ethoxy-2-methylbenzoyl)phenyl]amino]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 321350-98-5 CAPLUS  
CN Acetamide, N-[5-bromo-2-[(3-chloro-4-(2,4,5-trimethylbenzoyl)phenyl]amino]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 321350-99-6 CAPLUS  
CN Acetamide, N-[5-bromo-2-[(3-chloro-4-(4-fluoro-2-methylbenzoyl)phenyl]amino]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




IT 321351-02-4 321351-03-5 321351-04-6  
321351-06-8 321351-07-9 321351-08-0  
321351-09-1  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of aminobenzophenones as inhibitors of IL-1 $\beta$  and  
TNF- $\alpha$ )  
RN 321351-02-4 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](2,3-dimethylphenyl)- (CA INDEX NAME)




RN 321351-03-5 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](4-butyl-2-methylphenyl)- (CA INDEX NAME)




RN 321351-04-6 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](4-chloro-2-methylphenyl)- (CA INDEX NAME)




RN 321351-06-8 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](2,5-dimethylphenyl)- (CA INDEX NAME)




RN 321351-07-9 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](3-chloro-2-methylphenyl)- (CA INDEX NAME)



RN 321351-08-0 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-fluorophenyl](4-methoxy-2-methylphenyl)- (CA INDEX NAME)



RN 321351-09-1 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](4-ethoxy-2-methylphenyl)- (CA INDEX NAME)





REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2001:63954 CAPLUS  
DOCUMENT NUMBER: 134:115750  
TITLE: Preparation of novel aminobenzophenones as anti-acne agents  
INVENTOR(S): Ottosen, Erik Rytter; Bjorkling, Fredrik  
PATENT ASSIGNEE(S): Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktie, Den.  
SOURCE: PCT Int. Appl., 38 pp.

CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005744	A1	20010125	WO 2000-DK384	20000711
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2379316	A1	20010125	CA 2000-2379316	20000711
EP 1202954	A1	20020508	EP 2000-943698	20000711
EP 1202954	B1	20031001		
R: AI, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
HU 2002001910	A2	20021228	HU 2002-1910	20000711
HU 2002001910	A3	20060328		
JP 2003505359	T	20030212	JP 2001-511405	20000711
AT 251117	T	20031015	AT 2000-943698	20000711
AU 768473	B2	20031211	AU 2000-58067	20000711
PT 1202954	T	20040227	PT 2000-943698	20000711
NZ 516824	A	20040326	NZ 2000-516824	20000711
ES 2204639	T3	20040501	ES 2000-943698	20000711
RU 2243964	C2	20050110	RU 2002-103862	20000711
US 6624199	B1	20030923	US 2002-30965	20020222
HK 1048304	A1	20060421	HK 2003-100579	20030123
PRIORITY APPLN. INFO.:			US 1999-144065P	P 19990716
			WO 2000-DK384	W 20000711
OTHER SOURCE(S):	MARPAT 134:115750			
GI				




**AB** The title compds. (I; R1 = OH, halo, alkyl, etc.; R2 = H, OH, halo, etc.; R3 = halo, OH, SH, etc.; R6 = H, Me), useful for the prophylaxis and/or treatment of acne and acne related skin disorders, were prepared. Thus, reduction of 4-(4-bromo-2-nitrophenylamino)-2-chloro-2'-methylbenzophenone with stannous chloride in EtOH afforded I [R1 = 2-Me; R2 = Cl; R3 = 4-Br; R6 = H] which showed  $\geq 50\%$  inhibition of TPA-induced chronic skin inflammation in the mouse ear. Use of the title compds. II [R1, R2 = H, halo, OH, etc.; R3 = H, halo, OH, etc.; R4-R6 = H, CF<sub>3</sub>, alkyl, etc.; X = O, N(OH), N(Oalkyl), etc.] for the prophylaxis and/or treatment of acne and acne related skin disorders, is claimed.

**IT** 321377-90-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of novel aminobenzophenones as anti-acne agents)

**RN** 321377-90-6 CAPLUS

**CN** Methanone, [4-[(2-aminophenyl)amino]-2-chlorophenyl](2-chloro-4-methoxyphenyl)- (CA INDEX NAME)




**IT** 210966-49-7P 321351-02-4P 321351-03-5P  
321351-04-6P 321351-06-8P 321351-07-9P  
321351-08-0P 321351-09-1P 321359-20-0P  
321359-21-1P 321377-91-7P 321377-92-8P

321377-95-1P 321377-96-2P 321378-16-9P  
321378-17-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of novel aminobenzophenones as anti-acne agents)


RN 210966-49-7 CAPLUS

CN Methanone, [4-[(2-aminophenyl)amino]-2-chlorophenyl](4-fluoro-2-methylphenyl)- (CA INDEX NAME)




RN 321351-02-4 CAPLUS

CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](2,3-dimethylphenyl)- (CA INDEX NAME)




RN 321351-03-5 CAPLUS

CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](4-butyl-2-methylphenyl)- (CA INDEX NAME)




RN 321351-04-6 CAPLUS


CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](4-chloro-2-methylphenyl)- (CA INDEX NAME)




RN 321351-06-8 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](2,5-dimethylphenyl)- (CA INDEX NAME)




RN 321351-07-9 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](3-chloro-2-methylphenyl)- (CA INDEX NAME)




RN 321351-08-0 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-fluorophenyl](4-methoxy-2-methylphenyl)- (CA INDEX NAME)




RN 321351-09-1 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](4-ethoxy-2-methylphenyl)- (CA INDEX NAME)




RN 321359-20-0 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](2,4,5-trimethylphenyl)- (CA INDEX NAME)



RN 321359-21-1 CAPLUS  
CN Methanone, [4-[(2-amino-4-bromophenyl)amino]-2-chlorophenyl](4-fluoro-2-methylphenyl)- (CA INDEX NAME)




RN 321377-91-7 CAPLUS  
CN Methanone, [4-[(2-aminophenyl)amino]-2-chlorophenyl](2,3-dichloro-4-methoxyphenyl)- (CA INDEX NAME)




RN 321377-92-8 CAPLUS

CN Methanone, [4-[(2-aminophenyl)amino]-2-chlorophenyl](2,6-dichloro-4-methoxyphenyl)- (CA INDEX NAME)




RN 321377-95-1 CAPLUS

CN Methanone, [4-[(2-aminophenyl)amino]-2-chlorophenyl](2-chloro-4-hydroxyphenyl)- (CA INDEX NAME)




RN 321377-96-2 CAPLUS

CN Methanone, [4-[(2-aminophenyl)amino]-2-chlorophenyl](2,4-dichloro-6-hydroxyphenyl)- (CA INDEX NAME)




RN 321378-16-9 CAPLUS

CN Methanone, [4-[(2-aminophenyl)amino]-2-chlorophenyl](3-fluoro-2-methylphenyl)- (CA INDEX NAME)



RN 321378-17-0 CAPLUS

CN Methanone, [4-[(2-aminophenyl)amino]-2-chlorophenyl](4-methoxy-2,6-dimethylphenyl)- (CA INDEX NAME)



IT 321378-20-5 321378-21-6 321378-22-7

321378-25-0 321378-27-2 321378-40-9

321378-41-0 321378-42-1 321378-43-2

321378-45-4 321378-46-5 321378-47-6


321378-48-7 321378-49-8

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of novel aminobenzophenones as anti-acne agents)


RN 321378-20-5 CAPLUS

CN Methanone, (2-chloro-4-methoxyphenyl)[2-chloro-4-[(2-nitrophenyl)amino]phenyl]- (CA INDEX NAME)




RN 321378-21-6 CAPLUS


CN Methanone, [2-chloro-4-[(2-nitrophenyl)amino]phenyl](2,3-dichloro-4-methoxyphenyl)- (CA INDEX NAME)




RN 321378-22-7 CAPLUS  
CN Methanone, [2-chloro-4-[(2-nitrophenyl)amino]phenyl](2,6-dichloro-4-methoxyphenyl)- (CA INDEX NAME)



RN 321378-25-0 CAPLUS  
CN Methanone, [4-[(4-bromo-2-nitrophenyl)amino]-2-chlorophenyl](4-ethoxy-2-methylphenyl)- (CA INDEX NAME)




RN 321378-27-2 CAPLUS  
CN Methanone, [2-chloro-4-[(2-nitrophenyl)amino]phenyl](2,4-dichloro-6-hydroxyphenyl)- (CA INDEX NAME)




RN 321378-40-9 CAPLUS  
CN Methanone, [2-chloro-4-[(2-nitrophenyl)amino]phenyl](3-fluoro-2-

methylphenyl)- (CA INDEX NAME)




RN 321378-41-0 CAPLUS

CN Methanone, [4-[(4-bromo-2-nitrophenyl)amino]-2-chlorophenyl](2,3-dimethylphenyl)- (CA INDEX NAME)




RN 321378-42-1 CAPLUS

CN Methanone, [4-[(4-bromo-2-nitrophenyl)amino]-2-chlorophenyl](4-butyl-2-methylphenyl)- (CA INDEX NAME)




RN 321378-43-2 CAPLUS

CN Methanone, [4-[(4-bromo-2-nitrophenyl)amino]-2-chlorophenyl](4-chloro-2-methylphenyl)- (CA INDEX NAME)




RN 321378-45-4 CAPLUS

CN Methanone, [4-[(4-bromo-2-nitrophenyl)amino]-2-chlorophenyl](2,4,5-trimethylphenyl)- (CA INDEX NAME)




RN 321378-46-5 CAPLUS

CN Methanone, [4-[(4-bromo-2-nitrophenyl)amino]-2-chlorophenyl](4-fluoro-2-methylphenyl)- (CA INDEX NAME)




RN 321378-47-6 CAPLUS

CN Methanone, [4-[(4-bromo-2-nitrophenyl)amino]-2-chlorophenyl](2,5-dimethylphenyl)- (CA INDEX NAME)




RN 321378-48-7 CAPLUS

CN Methanone, [4-[(4-bromo-2-nitrophenyl)amino]-2-chlorophenyl](3-chloro-2-methylphenyl)- (CA INDEX NAME)



RN 321378-49-8 CAPLUS  
 CN Methanone, [4-[(4-bromo-2-nitrophenyl)amino]-2-fluorophenyl](4-methoxy-2-methylphenyl)- (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4. ANSWER 15 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1998:527309 CAPLUS  
 DOCUMENT NUMBER: 129:148822  
 ORIGINAL REFERENCE NO.: 129:30336h,30337a  
 TITLE: Preparation and formulation of aminobenzophenones as inhibitors of interleukin and TNF  
 Ottosen, Erik Rytter; Rachlin, Schneur  
 INVENTOR(S):  
 PATENT ASSIGNEE(S): Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktiebolag, Den.  
 SOURCE: PCT Int. Appl., 81 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9832730	A1	19980730	WO 1998-DK8	19980108
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MM, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RM: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2278798	A1	19980730	CA 1998-2278798	19980108

CA 2278798	C	20070703		
AU 9854781	A	19980818	AU 1998-54781	19980108
AU 733561	B2	20010517		
EP 966424	A1	19991229	EP 1998-900270	19980108
EP 966424	B1	20040623		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
NZ 336754	A	20010330	NZ 1998-336754	19980108
JP 2001511771	T	20010814	JP 1998-531499	19980108
HU 2000000678	A2	20011028	HU 2000-678	19980108
HU 2000000678	A3	20011128		
RU 2200153	C2	20030310	RU 1999-118221	19980108
AT 269844	T	20040715	AT 1998-900270	19980108
PT 966424	T	20040930	PT 1998-900270	19980108
ES 2223116	T3	20050216	ES 1998-900270	19980108
RO 120195	B1	20051028	RO 1999-839	19980108
US 6313174	B1	20011106	US 1999-341923	19990721
HK 1025306	A1	20050630	HK 2000-104495	20000721
PRIORITY APPLN. INFO.:				
MAPAT 129:148822				
OTHER SOURCE(S):				
GI				



**AB** The title compds. I [R1 and R2 stand independently for one or more, similar or different substituents selected from the group consisting of hydrogen, halogen, hydroxy, mercapto, trifluoromethyl, amino, alkyl, alkoxy, alkylthio, alkylamino, or alkoxy carbonyl, the C-content of which can be from 1 to 5, cyano, carboxy, carbamoyl, Ph, or nitro; R3 stands for hydrogen, halogen, hydroxy, mercapto, trifluoromethyl, amino, alkyl, alkoxy, alkylthio, alkylamino, or alkoxy carbonyl, the C-content of which can be from 1 to 5, Ph, cyano, carboxy, or carbamoyl; R4, R5 and R6 stand independently for hydrogen, trifluoromethyl, alkyl, carbamoyl, alkoxy carbonyl, or alkylxido, the C-content of which can be from 1 to 5; X stands for oxygen, NOH, NO-alkyl, dialkoxy, cyclic dialkoxy, dialkylthio, or cyclic dialkylthio, the C-content of which can be from 1 to 5] are prepared. The present compds. are of value in the human and veterinary practice as systemic and topical therapeutic agents for the treatment and prophylaxis of asthma, allergy, rheumatoid arthritis, spondyloarthritis, gout, atherosclerosis, chronic inflammatory bowel disease, proliferative and inflammatory skin disorders, such as psoriasis, and atopic dermatitis. In an *in vitro* test using human polymorphonuclear granulocytes, 4-(2-aminophenylamino)-2-chloro-2'-methylbenzophenone in *vitro* showed IC<sub>50</sub> of 13 nM and 7.1 nM against the production of IL-1 $\beta$  and TNF- $\alpha$ , resp. In the above test, 4-(2-aminophenylamino)benzophenone (II) in *vitro*


showed IC<sub>50</sub> of 250 nM and 790 nM against the production of IL-1 $\beta$  and TNF- $\alpha$ , resp. In the 12-O-tetradecanoylphorbol-13-acetate induced murine skin inflammation model, II showed activity equal to hydrocortisone.

IT 210966-06-6P 210966-46-4P 210966-49-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of aminobenzophenones as inhibitors of interleukin and TNF)


RN 210966-06-6 CAPLUS

CN Methanone, [4-[(2-aminophenyl)amino]-2-chlorophenyl](4-chlorophenyl)- (CA INDEX NAME)




RN 210966-46-4 CAPLUS

CN Methanone, [4-[(2-aminophenyl)amino]-2-chlorophenyl](2,4,5-trifluorophenyl)- (CA INDEX NAME)



RN 210966-49-7 CAPLUS

CN Methanone, [4-[(2-aminophenyl)amino]-2-chlorophenyl](4-fluoro-2-methylphenyl)- (CA INDEX NAME)




IT 210966-81-7P 210967-11-6P 210967-15-0P

210967-17-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of aminobenzophenones as inhibitors of interleukin and TNF)


RN 210966-81-7 CAPLUS

CN Methanone, [2-chloro-4-[(2-nitrophenyl)amino]phenyl](4-chlorophenyl)- (CA INDEX NAME)




RN 210967-11-6 CAPLUS

CN Methanone, [2-chloro-4-[(2-nitrophenyl)amino]phenyl](4-methoxy-2,6-dimethylphenyl)- (CA INDEX NAME)




RN 210967-15-0 CAPLUS

CN Methanone, [2-chloro-4-[(2-nitrophenyl)amino]phenyl](2,4,5-trifluorophenyl)- (CA INDEX NAME)



RN 210967-17-2 CAPLUS

CN Methanone, [2-chloro-4-[(2-nitrophenyl)amino]phenyl](4-fluoro-2-methylphenyl)- (CA INDEX NAME)




REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1983:98867 CAPLUS  
 DOCUMENT NUMBER: 98:98867  
 ORIGINAL REFERENCE NO.: 98:14935a,14938a  
 TITLE: Phthalide derivatives and a recording system utilizing them as colorless chromogenic material  
 INVENTOR(S): Misturi, Kondo; Tomoyuki, Okimoto; Nobuo, Kanda  
 PATENT ASSIGNEE(S): Kanzaki Paper Mfg. Co., Ltd., Japan  
 SOURCE: Eur. Pat. Appl., 68 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 62544	A1	19821013	EP 1982-301885	19820408
EP 62544	B1	19870930		
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
JP 57167979	A	19821016	JP 1981-53678	19810408
JP 63051113	B	19881012		
JP 58157779	A	19830919	JP 1982-39965	19820313
JP 04004316	B	19920127		
EP 127203	A1	19841205	EP 1984-200378	19820408
EP 127203	B1	19890628		
R: CH, DE, FR, GB, LI				
US 4641160	A	19870203	US 1984-667805	19841102
US 4748148	A	19880531	US 1986-929786	19861113
PRIORITY APPLN. INFO.:				
			JP 1981-53678	A 19810408
			JP 1982-39965	A 19820313
			US 1982-366338	A1 19820407
			EP 1982-301885	P 19820408
			US 1984-667805	A3 19841102
OTHER SOURCE(S):	CASREACT 98:98867; MARPAT 98:98867			
GI				



**AB** A colorless chromogenic material for use in the various recording systems (pressure-sensitive copying, thermal, electrothermal, ultrasonic, electron-beam, electrostatic and optical) which provides color images with good UV resistance and good IR absorption comprises phthalide derivative I [R1 = H, halogen, alkyl, alkoxy, NO<sub>2</sub>, amino; R2 = H, alkyl; R3-R6 = H, alkyl, aralkyl, aryl or R3 + R4 together with adjacent N or R5 + R6 with adjacent N form heterocyclic ring; R8, R9 = H, alkyl, alkoxy; R7 = H, halogen, alkyl, alkoxy, NO<sub>2</sub>, II, III (where Z = O, CH<sub>2</sub> and a + b ≥ 3)].

Thus, a base support was coated with a composition comprising a liquid 1 (containing

3-(p-methoxyphenyl)-3-[1,1-bis(p-dimethylaminophenyl)-ethylene-2-yl]-6-dimethylaminophthalide 5, stearic acid amine 1, 2% aqueous hydroxyethylcellulose 25 parts) 62, a liquid 2 (containing 4,4'-isopropenylidenediphenol 50, stearic acid amide 10, 2% aqueous hydroxyethylcellulose 250 parts) 31, Sylloid 244 25, 20% aqueous solution of a salt of styrene-maleic anhydride copolymer 175, Zn stearate 5, and H<sub>2</sub>O 100 parts to give a heat-sensitive recording material which was pressed with pressure of 4 kg/cm<sup>2</sup> for 5 s on a plate heated at 125° to develop blue-green images. The images had superior light resistance.


IT 84610-77-5

RL: USES (Uses)

(reaction with ethylene derivative, in preparation of chromogenic phthalide derivative for recording systems)

RN 84610-77-5 CAPLUS

CN Benzoic acid, 2-(4-methoxybenzoyl)-5-[methyl(4-methylphenyl)amino]-(CA INDEX NAME)



L4 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1975:581104 CAPLUS

DOCUMENT NUMBER: 83:181104

ORIGINAL REFERENCE NO.: 83:28465a,28468a

TITLE: Anthraquinone dyes

INVENTOR(S): Jost, Max

PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.

SOURCE: Ger. Offen., 26 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2501084	A1	19750717	DE 1975-2501084	19750113
CH 596269	A5	19780315	CH 1974-570	19740116
US 3956324	A	19760511	US 1975-540058	19750110
JP 50107037	A	19750823	JP 1975-6967	19750114
CA 1060009	A1	19790807	CA 1975-217870	19750114
GB 1453547	A	19761027	GB 1975-1674	19750115
FR 2257649	A1	19750808	FR 1975-1248	19750116
PRIORITY APPLN. INFO.:			CH 1974-570	A 19740116
GI	For diagram(s), see printed CA Issue.			
AB	Reaction of aminoanthraquinones RNH <sub>2</sub> (R = 1-anthraquinonyl, substituted 1-anthraquinonyl, 1,9-isothiazolanthron-5-yl) with tri- and tetrachlorobenzophenones gave fast red, gray-violet, and brown-orange dyes (I, m and n = 0, 1, or 2; R <sub>1</sub> = H or NHR) suitable for melt incorporation in poly(ethylene terephthalate). Thus, a mixture of 2,2',4,4'-tetrachlorobenzophenone [25187-08-0], 1-aminoanthraquinone [82-45-1], Na <sub>2</sub> CO <sub>3</sub> , and CuCl in PhNO <sub>2</sub> was heated and stirred 4 hr at the boil to give dye I [RNH = R <sub>1</sub> = anthraquinonylamino (2,2',4,4'-positions); m = n = 0] [56795-05-2], m. 190-8°, which mass dyed polyester a fast red shade. Twenty-seven other I were prepared			
IT	56794-82-2 56794-83-3 56794-84-4 56794-85-5 56794-86-6 56794-88-8 56794-89-9 56794-90-2 56794-91-3 56794-92-4 56794-94-6 56794-95-7 56794-98-0 56795-01-8 56795-02-9 56795-03-0 56795-04-1 56795-05-2			
RL: USES (Uses)	(dye, for polyester melts, preparation of)			
RN	56794-82-2 CAPLUS			
CN	6H-Antha[9,1-cd]isothiazol-6-one, 7,7'-(1-[4-[(6-oxo-6H-antha[9,1-cd]isothiazol-7-yl)amino]benzoyl]-1,3-phenylene)diimino]bis- (9CI) (CA			


INDEX NAME)



RN 56794-83-3 CAPLUS

CN Benzamide, N,N'-[{4-[4-[(4-(benzoylamino)-9,10-dihydro-9,10-dioxo-1-anthracyenyl]amino)benzoyl]-1,3-phenylene]bis[imino(9,10-dihydro-9,10-dioxo-4,1-anthracenediyil)]}bis- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 56794-84-4 CAPLUS  
CN Benzamide, N,N'-[(4-[4-[(5-(benzoylamino)-9,10-dihydro-9,10-dioxo-1-anthracenyl]amino]benzoyl]-1,3-phenylene)bis(imino(9,10-dihydro-9,10-dioxo-5,1-anthracenediyil))]bis- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 56794-85-5 CAPLUS  
CN 9,10-Anthracenedione, 1,1'-(4-[4-[(9,10-dihydro-9,10-dioxo-4-(phenylthio)-1-anthracenyl]amino]benzoyl]-1,3-phenylene)diiminobis[4-(phenylthio)- (9CI) (CA INDEX NAME)



RN 56794-86-6 CAPLUS


CN 9,10-Anthracenedione, 1,1'-[{4-[4-[(9,10-dihydro-9,10-dioxo-5-(phenylthio)-1-anthracenyl]amino]benzoyl}-1,3-phenylene]diimino]bis[5-(phenylthio)- (9CI) (CA INDEX NAME)



RN 56794-88-8 CAPLUS

CN Benzamide, N,N',N'',N'''-[carbonylbis[1,2,4-benzenetriylbis(imino(9,10-dihydro-9,10-dioxo-4,1-anthracenediyl))]]tetrakis- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 56794-89-9 CAPLUS

CN Benzamide, N,N',N'',N'''-[carbonylbis[1,2,4-benzenetriylbis[imino(9,10-dihydro-9,10-dioxo-5,1-anthracenediyl)]]]tetrakis- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 56794-90-2 CAPLUS


CN 9,10-Anthracenedione, 1,1',1'',1'''-[carbonylbis(1,2,4-benzenetriylidimino)]tetrakis[4-(phenylthio)- (9CI) (CA INDEX NAME)



RN 56794-91-3 CAPLUS  
CN 9,10-Anthracenedione, 1,1',1'',1'''-[carbonylbis(1,2,4-benzenetriylidimino)]tetrakis[5-(phenylthio)-] (9CI) (CA INDEX NAME)




RN 56794-92-4 CAPLUS  
CN 6H-Anthra[9,1-cd]isothiazol-6-one, 7,7',7'',7'''-[carbonylbis(1,2,4-benzenetriylidimino)]tetrakis- (9CI) (CA INDEX NAME)




RN 56794-94-6 CAPLUS

CN 9,10-Anthracenenedione, 1,1'-(2-[4-[(9,10-dihydro-9,10-dioxo-1-anthracyl)amino]-2,5-dimethylbenzoyl]-1,4-phenylene)diimino]bis- (9CI)  
(CA INDEX NAME)




RN 56794-95-7 CAPLUS

CN 9,10-Anthracenenedione, 1,1'-(4-[(9,10-dihydro-9,10-dioxo-1-anthracyl)amino]-2,5-dimethylbenzoyl)-1,3-phenylene)diimino]bis- (9CI)  
(CA INDEX NAME)




RN 56794-98-0 CAPLUS

CN 9,10-Anthracenedione, 1,1'-(4-[3-[(9,10-dihydro-9,10-dioxo-1-anthracyl)amino]benzoyl]-1,3-phenylene)diimino]bis- (9CI) (CA INDEX NAME)



RN 56795-01-8 CAPLUS


CN 9,10-Anthracenedione, 1,1'-(5-[2,4-bis[(9,10-dihydro-9,10-dioxo-1-anthracyl)amino]benzoyl]-2-methyl-1,3-phenylene)diimino]bis- (9CI) (CA INDEX NAME)




RN 56795-02-9 CAPLUS

CN Benzamide, N,N'-[{5-[2,4-bis[{4-(benzoylamino)-9,10-dihydro-9,10-dioxo-1-anthracenyl}amino]benzoyl]-2-methyl-1,3-phenylene]bis{imino(9,10-dihydro-9,10-dioxo-4,1-anthracenediyi)}]]bis- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




PAGE 3-A




RN 56795-03-0 CAPLUS

CN 9,10-Anthracenedione, 1,1'-[5-[2,4-bis([9,10-dihydro-9,10-dioxo-5-(phenylthio)-1-anthracenyl]amino)benzoyl]-2-methyl-1,3-phenylene]diimino]bis[5-(phenylthio)- (9CI) (CA INDEX NAME)




RN 56795-04-1 CAPLUS

CN 6H-Anthra[9,1-cd]isothiazol-6-one, 7,7'-(5-[2,4-bis[(6-oxo-6H-anthra[9,1-cd]isothiazol-7-yl)amino]benzoyl]-2-methyl-1,3-phenylene)diimino]bis-(9CI) (CA INDEX NAME)



RN 56795-05-2 CAPLUS

CN 9,10-Anthracenedione, 1,1',1'',1'''-[carbonylbis(1,2,4-phenylenetriylidene)diimino]tetrakis- (9CI) (CA INDEX NAME)




IT 56794-80-0P

RL: IMF (Industrial manufacture); PREP (Preparation)  
(preparation of)

RN 56794-80-0 CAPLUS


CN 9,10-Anthracenedione, 1,1'-[{4-[4-[(9,10-dihydro-9,10-dioxo-1-anthracenyl)amino]benzoyl]-1,3-phenylene}diimino]bis- (9CI) (CA INDEX NAME)



L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1975:481221 CAPLUS  
 DOCUMENT NUMBER: 83:81221  
 ORIGINAL REFERENCE NO.: 83:12761a,12764a  
 TITLE: Fluoran derivatives  
 INVENTOR(S): Hotta, Seiji; Ito, Yukiaki; Hatori, Minoru  
 PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 21 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 50018525	A	19750227	JP 1973-69558	19730619
PRIORITY APPLN. INFO.:			JP 1973-69558	A 19730619

GI For diagram(s), see printed CA Issue.  
 AB Fluoran derivs. (I; R = H, halogen, NO<sub>2</sub>; m = 1-4; R<sub>1</sub> is X-substituted phenyl or naphthyl; R<sub>2</sub> = H, lower alkyl, lower alkoxyalkyl, lower haloalkyl, lower hydroxylalkyl, lower cyanoalkyl, or X-substituted benzyl or  $\alpha$ -naphthylmethyl; R<sub>3</sub> and R<sub>4</sub> are H, lower alkyl, lower alkoxyalkyl, lower hydroxylalkyl, lower cyanoalkyl, cyclohexyl, or X-substituted phenyl,  $\alpha$ -naphthyl, benzyl, or  $\alpha$ -naphthylmethyl, or NR<sub>3</sub>R<sub>4</sub> is morpholino, piperidino, or pyrrolidino; R<sub>5</sub> = H, halogen, lower alkyl, or lower alkoxy; X = H, lower alkyl, lower alkoxy, halogen, NO<sub>2</sub>, alkoxy carbonyl, alkylsulfonyl, amino, or mono- or dialkylamino) are prepared (1) by dehydrocondensation of x, 4-R<sub>5</sub>(R<sub>3</sub>R<sub>4</sub>N)C<sub>6</sub>H<sub>3</sub>OR<sub>6</sub> (R<sub>6</sub> = H or lower alkyl) with a 2-(4-amino-2-hydroxybenzoyl)benzoic acid derivative, (2) by condensing I (R<sub>3</sub> and/or R<sub>4</sub> = H) with an alkylating agent, (3) by dehydrocondensation of m-R<sub>1</sub>R<sub>2</sub>N<sub>2</sub>C<sub>6</sub>H<sub>4</sub>OH with an aminohydroxybenzoylbenzoic acid derivative, or (4) by condensing a 2-(4-halo-2-hydroxybenzoyl)benzoic acid derivative with x, 4-R<sub>5</sub>(R<sub>3</sub>R<sub>4</sub>N)C<sub>6</sub>H<sub>3</sub>OR<sub>6</sub> and aminating the product with R<sub>1</sub>R<sub>2</sub>NH. For example, I (R = C<sub>1</sub>, m = 4, R<sub>1</sub> = 2-MeC<sub>6</sub>H<sub>4</sub>, R<sub>2</sub> = R<sub>3</sub> = Me, R<sub>4</sub> = CH<sub>2</sub>Ph, R<sub>5</sub> = H) [55849-93-9] was prepared in 45% yield by heating 8.5 parts 2-(methylenamino)-6-[methyl( $\omega$ -tolyl)amino]tetrachlorofluoruran [55849-88-2] with 3.78 parts PhCH<sub>2</sub>Cl [100-44-7] in 100 parts DMF at 70-80° for 2 hr, adding NaHCO<sub>3</sub>, heating an addnl. 6 hr at 70-80°, and removing unreacted PhCH<sub>2</sub>Cl. The same product was obtained by heating a mixture of 10.8 parts 2-(benzylmethylamino)-6-chlorotetrachlorofluoruran [55849-91-7] and 3.7 parts 2-MeC<sub>6</sub>H<sub>4</sub>SO<sub>3</sub>H [611-21-2] containing 15 parts ZnCl<sub>2</sub> and 5 parts p-MeC<sub>6</sub>H<sub>4</sub>SO<sub>3</sub>H for 3 hr at 180-5° and 2 hr at 220-30°. Six other I were prepared by various of the specified methods. The fluorans can be encapsulated in gelatin-gum arabic and used in pressure sensitive copying paper or used in paper coating compns. for heat-developed printing.  
 IT 55849-85-9  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reaction of, with (benzylmethylamino)phenol)  
 RN 55849-85-9 CAPLUS  
 CN Benzoic acid, 2,3,4,5-tetrachloro-6-[4-[(2,4-dimethylphenyl)methylamino]-2-hydroxybenzoyl]-(CA INDEX NAME)




IT 55849-83-7

RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction of, with (dibenzylamino)phenol)

RN 55849-83-7 CAPLUS

CN Benzoic acid, 2,3,4,5-tetrachloro-6-[2-hydroxy-4-(methylphenylamino)benzoyl]- (CA INDEX NAME)

RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction of, with (methylanilino)cresol)

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1975:481220 CAPLUS

DOCUMENT NUMBER: 83:81220

ORIGINAL REFERENCE NO.: 83:12760h,12761a

TITLE: Fluoran derivatives

INVENTOR(S): Hotta, Seiji; Ito, Yukiaki; Hatori, Minoru

PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 18 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 50014725	A	19750217	JP 1973-65075	19730608
PRIORITY APPLN. INFO.:			JP 1973-65075	A 19730608

GI For diagram(s), see printed CA Issue.  
AB Fluorans (I; R = H, NO<sub>2</sub>, halogen; m = 1-4; R<sub>1</sub> is X-substituted phenyl or


naphthyl; R2 is H, lower alkyl, lower alkoxyalkyl, lower haloalkyl, lower hydroxalkyl, lower cyanoalkyl, or X-substituted benzyl or  $\alpha$ -naphthylmethyl; R3, R4 are H, lower alkyl, lower alkoxyalkyl, lower haloalkyl, lower hydroxalkyl, lower cyanoalkyl, cycloalkyl, or X-substituted phenyl, benzyl, naphthyl, or  $\alpha$ -naphthylmethyl; R5 is H, halogen, lower alkyl, or lower alkoxy; and X is H, lower alkyl, lower alkoxy, halogen, NO<sub>2</sub>, alkoxy carbonyl, alkylsulfonyl, NH<sub>2</sub>, or alkyl- or dialkylamino; also, NR3R4 may be morpholino, piperidino, or pyrrolidino) are prepared by (1) dehydrocondensation of an aminonaphthal derivative with a 2-(4-amino-2-hydroxybenzoyl)benzoic acid derivative, (2) condensation of I (R3 and/or R4 = H) with an alkylating agent, (3) dehydrocondensation of a m-aminophenol derivative with a 2-(4-amino-1-hydroxy-2-naphthoyl)benzoic acid derivative, or (4) condensation of an aminonaphthal derivative with a 2-(4-halo-2-hydroxybenzoyl)benzoic acid derivative, followed by substitution of the halogen with R1R2NH. For example, I (R = R4 = R5 = H, R1 = Ph, R2 = Me, R3 = 2,4,6-Me<sub>3</sub>C<sub>6</sub>H<sub>2</sub>) [55914-49-3], a dark green dye which can be encapsulated for use in pressure-sensitive copying paper, was prepared in 60.5% yield by condensation of 4-mesidino-1-naphthol [55850-02-7] with 2,4-HO(PhNMe)C<sub>6</sub>H<sub>3</sub>COC<sub>6</sub>H<sub>4</sub>CO<sub>2</sub>H-2 [42529-88-4] in concentrated H<sub>2</sub>SO<sub>4</sub> for 10 hr at 20-30°, as well as by reaction of 2-mesidino-8-chlorofluoruran [55850-03-8] with PhNMe [100-61-8] in the presence of ZnCl<sub>2</sub> and p-C<sub>6</sub>H<sub>4</sub>SO<sub>3</sub>H for 3 hr at 180-5° and 2 hr at 220-30°. Seven other I were prepared by various of the specified methods.

IT 55849-83-7

RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction of, with anilinonaphthal)

BN 55849-83-7 CAPIUS

BN 55349-63-7 CAS#5  
CN Benzoic acid, 2,3,4,5-tetrachloro-6-[2-hydroxy-4-(methylphenylamino)benzoyl]- (CA INDEX NAME)



L4 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1971:498279 CAPLUS

DOCUMENT NUMBER: 75:98279

ORIGINAL REFERENCE NO.: 75:15537a, 15540a

TITLE: Reaction of polyfluoro aromatic ketones with aniline  
AUTHOR(S): Vasilevskaya, T. N.; Baturina, I. I.; Kollegova, M.  
I.; Gerasimova, T. N.; Barkhash, V. A.

CORPORATE SOURCE: Novosib. Inst. Org. Khim., Novosibirsk, USSR  
SOURCE: Zhurnal Organicheskoi Khimii (1971), 7(6), 1230-9  
CODEN: ZORKAE ISSN: 0514-7492

DOCUMENT TYPE: Journal

AB PhNH<sub>2</sub> reacted with C6F<sub>5</sub>COR (I, R = C<sub>6</sub>F<sub>5</sub>, Ph, Me) neat or in ether solvents to give the corresponding o- and p-PhNHC<sub>6</sub>F<sub>4</sub>COR (II) and 9-substituted-1,2,4-trifluoro-3-anilino acridines (III). I (R = CF<sub>3</sub>) gave


the corresponding II and III with PhNH<sub>2</sub> in refluxing THF, but gave a mixture of C<sub>6</sub>F<sub>5</sub>C(.NPh)CF<sub>3</sub>, p-PhNC<sub>6</sub>F<sub>4</sub>C(.NPh)CF<sub>3</sub>, II (R = CF<sub>3</sub>), and 1,2,4-trifluoro-3-anilino-9-trifluoromethyl-9-hydroxyacridan at 75° in the absence of solvent. 9-Substituted-1,2,3,4-tetrafluoroacridines (IV) were synthesized from I (R = C<sub>6</sub>F<sub>5</sub>, Ph, Me) by treatment with concentrated H<sub>2</sub>SO<sub>4</sub> at 100°; IV yielded the corresponding III with PhNMe<sub>2</sub>.

IT 33539-03-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 33539-03-6 CAPLUS

CN Benzophenone, 4-anilino-2,2',3,3',4',5,5',6,6'-nonafluoro- (8CI) (CA INDEX NAME)



L4 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1969:523789 CAPLUS

DOCUMENT NUMBER: 71:123789

ORIGINAL REFERENCE NO.: 71:22987a,22990a

TITLE: Reaction of polyfluoroaromatic alcohols with nitric acid

AUTHOR(S): Anichkina, S. A.; Khramtsova, G. F.; Barkhash, V. A.; Vorozhtsov, N. N., Jr.

CORPORATE SOURCE: Novosibirsk Inst. Org. Khim., Novosibirsk, USSR

SOURCE: Zhurnal Obshchey Khimii (1969), 39(8), 1766-73

CODEN: ZOKHA4; ISSN: 0044-460X

DOCUMENT TYPE: Journal

LANGUAGE: Russian

AB Primary and secondary polyfluoroaromatic alcs. with a OH in the 1-position relative to C<sub>6</sub>F<sub>5</sub> group can form stable nitrates with fuming HNO<sub>3</sub>. Such a nitrate of (C<sub>6</sub>F<sub>5</sub>)<sub>2</sub>CHOH can react with nucleophiles by acid-base route to form (C<sub>6</sub>F<sub>5</sub>)<sub>2</sub>CO and products of nucleophilic replacement of F in the latter. RMgCl, from 20.3 g. C<sub>6</sub>F<sub>5</sub>Cl, formed with Mg and BrCH<sub>2</sub>CH<sub>2</sub>Br in Et<sub>2</sub>O, was treated with MeCOEt to yield, in 15 hrs. at room temperature followed by hydrolysis, 70.5% C<sub>6</sub>F<sub>5</sub>CMcEtOH, b7 78°, n<sub>20D</sub> 1.4490. Treating the title alcs. with 10 parts HNO<sub>3</sub> (d. 1.5) at room temperature 1 day, gave on dilution the following products: 57% C<sub>6</sub>F<sub>5</sub>CH<sub>2</sub>ONO<sub>2</sub>, b2 74°, n<sub>21D</sub> 1.4470; 55% C<sub>6</sub>F<sub>5</sub>CHMeONO<sub>2</sub>, b3 75-5.5°, n<sub>17D</sub> 1.4457; 60% C<sub>6</sub>F<sub>5</sub>CMc(OH)CH<sub>2</sub>NO<sub>2</sub>, b4 122-4°, m. 43-4.5°; (C<sub>6</sub>F<sub>5</sub>)<sub>2</sub>CO(OH)CH<sub>2</sub>NO<sub>2</sub>, m. 105-11°; 69% C<sub>6</sub>F<sub>5</sub>CMc(OH)CHMeNO<sub>2</sub>, b6 124°, n<sub>25D</sub> 1.4680. Passing dry NH<sub>3</sub> into (C<sub>6</sub>F<sub>5</sub>)<sub>2</sub>CHONO<sub>2</sub> 3 hrs. gave after an aqueous treatment 63.5% (C<sub>6</sub>F<sub>5</sub>)<sub>2</sub>CO and 14% p-H<sub>2</sub>NC<sub>6</sub>F<sub>4</sub>CO<sub>2</sub>C<sub>6</sub>F<sub>5</sub> (I), m. 147-8°, provided the reaction is run at 90-5°; at room temperature 86% of the former ketone only was attained. Similar reaction with PhNH<sub>2</sub> in Et<sub>2</sub>O overnight gave 14% (C<sub>6</sub>F<sub>5</sub>)<sub>2</sub>CO and the anilino analog of I, m. 113-15°. Similar reaction of the nitrate with KI in Me<sub>2</sub>CO gave 41%


(C<sub>6</sub>F<sub>5</sub>)<sub>2</sub>CO. C<sub>6</sub>F<sub>5</sub>CMe(OH)CH<sub>2</sub>NO<sub>2</sub> (II) 20 min. with 20% NaOH gave 45% AcC<sub>6</sub>F<sub>5</sub>, b6 65%, also formed similarly from C<sub>6</sub>F<sub>5</sub>CMe(OH)CHMeNO<sub>2</sub> in 66% yield; similar reaction of (C<sub>6</sub>F<sub>5</sub>)<sub>2</sub>C(OH)CH<sub>2</sub>NO<sub>2</sub> gave 59% (C<sub>6</sub>F<sub>5</sub>)<sub>2</sub>CO. II heated with P205 1 hr. at 150°, then treated with ice, gave 85% cis-trans isomers of C<sub>6</sub>F<sub>5</sub>CMe:CHNO<sub>2</sub>, b5 11°, n<sub>D</sub><sup>25</sup> 1.4690, the product with trans Me and H groups being predominant in 1.5:1 ratio.  
(C<sub>6</sub>F<sub>5</sub>)<sub>2</sub>C(OH)CH<sub>2</sub>NO<sub>2</sub> treated with concentrated H<sub>2</sub>SO<sub>4</sub> 2 hrs. gave 53% (C<sub>6</sub>F<sub>5</sub>)<sub>2</sub>C:CHNO<sub>2</sub>, m. 141-2.2°. Keeping C<sub>6</sub>F<sub>5</sub>CMe:CH<sub>2</sub> in HNO<sub>3</sub> 1 day gave 50% II. Similarly (C<sub>6</sub>F<sub>5</sub>)<sub>2</sub>C:CH<sub>2</sub> gave (C<sub>6</sub>F<sub>5</sub>)<sub>2</sub>C(OH)CH<sub>2</sub>NO<sub>2</sub> in 60% yield.

IT 33539-03-6P, Benzophenone, 4-anilino-2,2',3,3',4',5,5',6,6'-nonafluoro-

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 33539-03-6 CAPLUS

CN Benzophenone, 4-anilino-2,2',3,3',4',5,5',6,6'-nonafluoro- (8CI) (CA INDEX NAME)



L4 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 1958:32632 CAPLUS  
DOCUMENT NUMBER: 52:32632  
ORIGINAL REFERENCE NO.: 52:5841f-h  
TITLE: Acid nitro dyes  
INVENTOR(S): Tampke, Hans  
PATENT ASSIGNEE(S): Farberke Hoechst AG vorm. Meister Lucius & Bruning  
DOCUMENT TYPE: Patent  
LANGUAGE: Unavailable  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 838045		19520505	DE	


AB Yellow nitro dyes of the general formula [x,4-Z(O<sub>2</sub>N)NaO<sub>3</sub>SRNH<sub>2</sub>H<sub>2</sub>]<sub>2</sub>X are prepared, where X is a CO or SO<sub>2</sub> group, Z is Cl or H, R is a phenyl or naphthyl radical, by condensing aminoarenesulfonic acids, which may be substituted, with 4,4'-dihalo-3,3'-dinitrobenzophenone or diphenyl sulfone. Thus, 4,4'-dichloro-3,3'-dinitrobenzophenone (I) 34 and Na 1-amino-4-ethoxy-2-benzenesulfonate 100 are mixed at 100° to give a yellow wool dye of good fastness to light and alkali. I and 2,5-H<sub>2</sub>N(PhO)C<sub>6</sub>H<sub>3</sub>SO<sub>3</sub>Na (II) give a very wet-fast dye. Similarly dyes are prepared from bis(4-chloro-3-nitrophenyl) sulfone (III) and II; or I and Na 1-amino-4-methoxy-3-benzenesulfonic acid. In Ger. 838,046, similar dyes are prepared from I and the Na salt of metanilic acid; 4,4'-dibromo-3,3'-dinitrobenzophenone (IV) and NH<sub>4</sub> 1-amino-3,4-dimethyl-6-benzenesulfonate;

IV and NH4 1-amino-4-methyl-5-benzenesulfonate; or III and NH4  
1-amino-4-methyl-3-benzenesulfonate.

IT 108750-81-8P, 3,4-Xylenesulfonic acid, 6,6'-[carbonylbis[(2-nitro-p-phenylene)imino]di-, diammonium salt 114794-70-6P, Metanilic acid, N,N'-[carbonylbis(2-nitro-p-phenylene)]di-, disodium salt  
RL: PREP (Preparation)  
(preparation of)


RN 108750-81-8 CAPLUS

CN 3,4-Xylenesulfonic acid, 6,6'-[carbonylbis[(2-nitro-p-phenylene)imino]di-, diammonium salt (6CI) (CA INDEX NAME)



●2 NH<sub>3</sub>

RN 114794-70-6 CAPLUS  
CN Metanilic acid, N,N'-(carbonylbis(2-nitro-p-phenylene))di-, disodium salt  
(6CI) (CA INDEX NAME)



●2 Na

=> log h			
COST IN U.S. DOLLARS	SINCE FILE	TOTAL	
FULL ESTIMATED COST	ENTRY	SESSION	
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	120.86	299.43	
CA SUBSCRIBER PRICE	SINCE FILE	TOTAL	
	ENTRY	SESSION	
	-17.60	-17.60	

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 10:22:58 ON 01 AUG 2008